Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries	156	182	ANALYTICAL_METHOD	statistical interpretation
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	15	52	ANALYTICAL_METHOD	circRNA/miRNA/mRNA regulatory network
"009, logistic regression), when comparing \""best\"" and \""worst\"" risk groups"	6	25	ANALYTICAL_METHOD	logistic regression
Results were assessed by Cox model for survival and by logistic regression for response and toxicity	25	34	ANALYTICAL_METHOD	Cox model
Results were assessed by Cox model for survival and by logistic regression for response and toxicity	55	74	ANALYTICAL_METHOD	logistic regression
Logistic regression was applied to assess CYP2C19 polymorphism as an effect modifier of cyclophosphamide	0	19	ANALYTICAL_METHOD	Logistic regression
These models were evaluated within the PLATO software package using pair wise logistic regression models	68	104	ANALYTICAL_METHOD	pair wise logistic regression models
Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with regular use of NSAIDs and with relevant polymorphisms on ovarian cancer risk	0	31	ANALYTICAL_METHOD	Conditional logistic regression
Multivariable unconditional logistic regression estimated the association of NSAID use across stratum of each genotype	0	47	ANALYTICAL_METHOD	Multivariable unconditional logistic regression
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	9	40	ANALYTICAL_METHOD	wrapper-based feature selection
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	63	100	ANALYTICAL_METHOD	multilayer feedforward neural network
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	112	131	ANALYTICAL_METHOD	logistic regression
Our data revealed that the MFNN models were superior to the logistic regression model	27	38	ANALYTICAL_METHOD	MFNN models
Our data revealed that the MFNN models were superior to the logistic regression model	60	85	ANALYTICAL_METHOD	logistic regression model
Our logistic regression analyses indicated the probability that 76% patients carrying combination of four SNPs will not show favorable response to AAP therapy	4	23	ANALYTICAL_METHOD	logistic regression
A multiple linear regression model revealed that the ABCC3 -211C/T polymorphism was not independently associated with ADP-induced MPA measurements; a multiple logistic regression model revealed that carrying the ABCC3 -211C allele was not associated with the risk of developing an ST event in clopidogrel-treated patients not harbouring CYP2C19*2, *3 and *17 variants	2	28	ANALYTICAL_METHOD	multiple linear regression
Seven candidate polymorphisms (rs3842 and rs1045642 in ABCB1, rs212091 and rs3743527 in ABCC1, rs3745274 in CYP2B6, rs628031 in SLC22A1 and rs1517618 in SLCO3A1) were evaluated if they were associated with virological failure through logistic regression analysis	234	253	ANALYTICAL_METHOD	logistic regression
Logistic regression including appropriate covariates was performed	0	19	ANALYTICAL_METHOD	Logistic regression
1 or less in the univariate analysis were included in a multiple regression analysis (logistic regression for adverse reactions)	56	75	ANALYTICAL_METHOD	multiple regression
1 or less in the univariate analysis were included in a multiple regression analysis (logistic regression for adverse reactions)	86	105	ANALYTICAL_METHOD	logistic regression
6% in the evaluation by means of logistic regression	33	52	ANALYTICAL_METHOD	logistic regression
A multivariate analysis by logistic regression confirmed its significant contribution (p = 0	2	23	ANALYTICAL_METHOD	multivariate analysis
A multivariate analysis by logistic regression confirmed its significant contribution (p = 0	27	46	ANALYTICAL_METHOD	logistic regression
Multivariate logistic regression revealed that five SNPs (rs11209026 in IL23R, rs10782001 in FBXL19, rs3087243 in CTLA4, rs651630 in SLC12A8 and rs1800453 in TAP1) were associated with paradoxical reactions	0	32	ANALYTICAL_METHOD	Multivariate logistic regression
Quality control of genome-wide data was performed according to standard criteria and linear/logistic regression models were used as appropriate under an additive hypothesis	85	111	ANALYTICAL_METHOD	linear/logistic regression
Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months	0	28	ANALYTICAL_METHOD	Multiple logistic regression
Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months	33	47	ANALYTICAL_METHOD	Cox regression
A sensitivity analysis of a secondary composite endpoint of TIA, stroke, or death demonstrated a significant trend in multiple logistic regression analysis of CYP2C19 variants, with lower odds of secondary endpoint in patients carrying at least 1 LOF allele (*2, *3, *8) than in wild-type homozygotes (OR 0	127	146	ANALYTICAL_METHOD	logistic regression
Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU	0	19	ANALYTICAL_METHOD	Logistic regression
Logistic regression was used to test for association between these polymorphisms and treatment response	0	19	ANALYTICAL_METHOD	Logistic regression
Multivariate logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR	0	32	ANALYTICAL_METHOD	Multivariate logistic regression
In a binary logistic regression analysis the odds ratio (OR) was 8	5	31	ANALYTICAL_METHOD	binary logistic regression
Association with toxicities was evaluated retrospectively using logistic regression analysis	64	83	ANALYTICAL_METHOD	logistic regression
A non-conditional logistic regression was used to identify the factors associated with hepatotoxicity	2	37	ANALYTICAL_METHOD	non-conditional logistic regression
Multivariate logistic regression analysis was used to structure a nomogram	0	32	ANALYTICAL_METHOD	Multivariate logistic regression
Univariate and multivariate statistical analysis by logistic regression revealed 10 SNPs associated with severe adverse reactions to capecitabine (P<0	52	71	ANALYTICAL_METHOD	logistic regression
The relation of SOCS1-1478 CA/del polymorphism to PCOS status and insulin resistance was analysed via logistic regression analysis	102	121	ANALYTICAL_METHOD	logistic regression
Odds ratios for HLA alleles and KIR types and HLA*KIR interactions using conditional logistic regressions were determined in the overall population and by race/ethnicity	73	105	ANALYTICAL_METHOD	conditional logistic regressions
The genetic associations were tested using logistic regression analyses	43	62	ANALYTICAL_METHOD	logistic regression
Logistic regression analysis showed that the dose of metoprolol and the genotypes of <i>CYP2D6</i> were predictors of heart rate\u00a0<70\u00a0beats/min in these patients	0	19	ANALYTICAL_METHOD	Logistic regression
Linear regression was performed for baseline weight and BMI <i>z</i>, while change in BMI <i>z</i> was assessed using random effects ordered logistic regression	0	17	ANALYTICAL_METHOD	Linear regression
Linear regression was performed for baseline weight and BMI <i>z</i>, while change in BMI <i>z</i> was assessed using random effects ordered logistic regression	118	161	ANALYTICAL_METHOD	random effects ordered logistic regression
Next, binary logistic regression was applied to evaluate the association of the PGSs to SSRIs treatment response in a discovery sample (ISPC, N\u2009=\u2009865), and in a replication cohort (STAR*D, N\u2009=\u20091,878)	6	32	ANALYTICAL_METHOD	binary logistic regression
<b>Conclusions:</b> This study did identify associations between <i>CHRM2</i> variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors	112	131	ANALYTICAL_METHOD	logistic regression
2) and clinical conditions in relation to severe (III-IV) adverse drug reactions (ADRs), stepwise forward multivariate logistic regression analyses were performed	119	138	ANALYTICAL_METHOD	logistic regression
Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the <i>SLC22A1</i>, <i>SLC22A2</i>, and <i>SLC22A3</i> genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (<i>p</i> < 0	26	45	ANALYTICAL_METHOD	logistic regression
Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively	0	23	ANALYTICAL_METHOD	Cox proportional hazard
Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively	28	47	ANALYTICAL_METHOD	logistic regression
The three top scoring SNPs (rs12248560, rs878567, rs17710780) were subsequently combined into an unweighted GRS, which was included in linear and logistic regression models using the CES-D score, occurrence of a major depressive episode (MDE) during follow-up and regular antidepressant treatment during the 6 months preceding follow-up assessment as outcomes	146	165	ANALYTICAL_METHOD	logistic regression
Linear and logistic regression analyses were used to assess predictors of withdrawal symptomatology	11	30	ANALYTICAL_METHOD	logistic regression
Logistic regression analysis showed that high SAMe-TT<sub>2</sub>R<sub>2</sub> score was the only statistically significant predicting factor of poor INR control (odds ratio (OR) 5	0	19	ANALYTICAL_METHOD	Logistic regression
Cox and logistic regression models with Elastic net penalty were employed	0	3	ANALYTICAL_METHOD	Cox
Cox and logistic regression models with Elastic net penalty were employed	8	27	ANALYTICAL_METHOD	logistic regression
In a logistic regression analysis, higher CYP2C19 activity (OR (95% CI): 4	5	24	ANALYTICAL_METHOD	logistic regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	15	31	ANALYTICAL_METHOD	machine learning
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	54	76	ANALYTICAL_METHOD	naive Bayes classifier
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	83	105	ANALYTICAL_METHOD	support vector machine
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	113	135	ANALYTICAL_METHOD	elastic net regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	144	163	ANALYTICAL_METHOD	logistic regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	170	186	ANALYTICAL_METHOD	lasso regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	194	234	ANALYTICAL_METHOD	multivariate adaptive regression splines
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	243	266	ANALYTICAL_METHOD	boosted regression tree
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	277	296	ANALYTICAL_METHOD	random forest model
We used a logistic regression model to identify patient variables that predicted successful enrollment after subjects were contacted and evaluated the reasons that clinical trial eligible subjects refused enrollment	10	29	ANALYTICAL_METHOD	logistic regression
Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ	0	33	ANALYTICAL_METHOD	Multivariable logistic regression
Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments	166	171	ANALYTICAL_METHOD	MFNNs
Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments	176	195	ANALYTICAL_METHOD	logistic regression
The association between genotypes, alleles and blood pressure response to treatment was determined by conducting multivariate logistic regression model analysis	113	145	ANALYTICAL_METHOD	multivariate logistic regression
<b>Methods:</b> We genotyped thirteen tagging and functional SNPs of <i>ABCG2</i> in 1004 patients, and assessed their association with response, toxicity and survival using unconditional logistic regression and Cox proportional hazards regression analyses respectively	188	207	ANALYTICAL_METHOD	logistic regression
<b>Methods:</b> We genotyped thirteen tagging and functional SNPs of <i>ABCG2</i> in 1004 patients, and assessed their association with response, toxicity and survival using unconditional logistic regression and Cox proportional hazards regression analyses respectively	212	247	ANALYTICAL_METHOD	Cox proportional hazards regression
In simulation data with added noises or CFs and in pharmacogenomic data, RePhine demonstrated an improved performance in comparison with three commonly used methods (including Pearson correlation analysis, logistic regression model, and gene set enrichment analysis)	176	195	ANALYTICAL_METHOD	Pearson correlation
In simulation data with added noises or CFs and in pharmacogenomic data, RePhine demonstrated an improved performance in comparison with three commonly used methods (including Pearson correlation analysis, logistic regression model, and gene set enrichment analysis)	206	225	ANALYTICAL_METHOD	logistic regression
We genotyped 16 polymorphisms in genes for enzymes involved in the folate-methionine pathway and in methotrexate transport, and analysed their association with treatment efficacy and toxicity using classification and regression tree analysis and logistic regression	246	265	ANALYTICAL_METHOD	logistic regression
We constructed the predictive model using logistic regression	42	61	ANALYTICAL_METHOD	logistic regression
Multiple logistic regression was then performed to identify the factors associated with rapid CKD progression	0	28	ANALYTICAL_METHOD	Multiple logistic regression
Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors	0	19	ANALYTICAL_METHOD	Logistic regression
Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression	164	184	ANALYTICAL_METHOD	univariable analysis
Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression	202	235	ANALYTICAL_METHOD	multivariate logistic regression
Logistic regressions were performed between PRSs and non-response or non-remission in six European clinical samples, adjusting for age, sex, baseline symptom severity, recruitment sites, and population stratification	0	20	ANALYTICAL_METHOD	Logistic regressions
Multivariable logistic regression analyzed the association between one or more gene-x-drug interactions with 90-day readmission	0	33	ANALYTICAL_METHOD	Multivariable logistic regression
Responses were assessed using multivariable logistic regression	30	63	ANALYTICAL_METHOD	multivariable logistic regression
Logistic regression was used for analysis	0	19	ANALYTICAL_METHOD	Logistic regression
Multivariable logistic regression analysis was employed to investigate the independent risk factors for bleeding and to develop a risk scoring system	0	33	ANALYTICAL_METHOD	Multivariable logistic regression
Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes	12	31	ANALYTICAL_METHOD	logistic regression
Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes	81	102	ANALYTICAL_METHOD	Kaplan-Meier analyses
Logistic regression model was used to analyze the correlation between the <i>CYP2D6</i> phenotype and incidence of adverse events, which were assessed over a 12-week period	0	19	ANALYTICAL_METHOD	Logistic regression
In logistic regression model, the overall incidence of adverse events was 1	3	22	ANALYTICAL_METHOD	logistic regression
Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model	79	112	ANALYTICAL_METHOD	multivariable logistic regression
Two logistic regression models accounted for two diplotypes in OCT1 and ABCB1, including statistically significant covariates	4	23	ANALYTICAL_METHOD	logistic regression
Our multinomial logistic regression results may benefit future predictive analyses in diabetic populations	4	35	ANALYTICAL_METHOD	multinomial logistic regression
Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of <i>ABCC4</i> gene as predisposing factors of RTD	0	30	ANALYTICAL_METHOD	Univariate logistic regression
Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression	60	79	ANALYTICAL_METHOD	Kaplan-Meier curves
Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression	84	107	ANALYTICAL_METHOD	Cox logistic regression
Multiple logistic regression analysis identified DRD2 -141C deletion [odds ratio (OR)\u2005=\u20051	0	28	ANALYTICAL_METHOD	Multiple logistic regression
Negative binomial regression and logistic regression were used	0	28	ANALYTICAL_METHOD	Negative binomial regression
Negative binomial regression and logistic regression were used	33	52	ANALYTICAL_METHOD	logistic regression
Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model	79	112	ANALYTICAL_METHOD	multivariable logistic regression
Logistic regression models were fitted to assess the impact of activity scores on symptom improvement and side effects	0	19	ANALYTICAL_METHOD	Logistic regression
We conducted logistic regression models to examine the association of genetic variants with CAA/L during acute KD and with persistence >6 weeks using an additive model between cases and 238 controls with no CAA	13	32	ANALYTICAL_METHOD	logistic regression
Genetic association analyses were conducted using the additive model and multivariable logistic regression	0	19	ANALYTICAL_METHOD	Genetic association
Genetic association analyses were conducted using the additive model and multivariable logistic regression	54	68	ANALYTICAL_METHOD	additive model
Genetic association analyses were conducted using the additive model and multivariable logistic regression	73	106	ANALYTICAL_METHOD	multivariable logistic regression
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	150	181	ANALYTICAL_METHOD	Genome-Wide Association Studies
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	190	207	ANALYTICAL_METHOD	Mass Spectrometry
It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text	69	85	ANALYTICAL_METHOD	machine learning
It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text	89	127	ANALYTICAL_METHOD	natural language processing approaches
In this literature-based study, we compared the performances of eight machine learning techniques with those of MLR in a large, racially-diverse cohort	70	86	ANALYTICAL_METHOD	machine learning
We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient's genotype and background	62	78	ANALYTICAL_METHOD	machine learning
Very recently, machine learning regression has been used to investigate how well cancer cell line sensitivity to drugs is predicted depending on the type of molecular profile	15	42	ANALYTICAL_METHOD	machine learning regression
R code to facilitate the construction of alternative machine learning models and their validation in the presented benchmark is available at http://ballester	53	69	ANALYTICAL_METHOD	machine learning
With machine learning and integrated pharmacogenomics and metabolomics, we demonstrate that KA efficacy is not determined by the status of individual genes, but by the quantitative extent of the WE, leading to a therapeutic window in\u00a0vivo	5	21	ANALYTICAL_METHOD	machine learning
Machine learning models showed that independent SNPs in this pathway predicted TRD with a mean sensitivity of 0	0	16	ANALYTICAL_METHOD	Machine learning
Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine	0	13	ANALYTICAL_METHOD	Deep learning
Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine	39	55	ANALYTICAL_METHOD	machine learning
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	147	163	ANALYTICAL_METHOD	machine learning
Among the identified small set of genes associated with reduced breast cancer incidence, laboratory experiments on one of the genes, CDC42, showed that its downregulation by metformin inhibited cancer cell migration and proliferation, thus validating the ability of machine learning approaches to identify biologically relevant candidates for laboratory experiments	266	282	ANALYTICAL_METHOD	machine learning
During the last decade, the interest to apply machine learning algorithms to genomic data has increased in many bioinformatics applications	46	62	ANALYTICAL_METHOD	machine learning
Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone	0	27	ANALYTICAL_METHOD	Supervised machine learning
Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone	32	49	ANALYTICAL_METHOD	feature selection
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	62	75	ANALYTICAL_METHOD	Linear Models
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	127	140	ANALYTICAL_METHOD	Decision Tree
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	145	158	ANALYTICAL_METHOD	Random Forest
This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project	150	173	ANALYTICAL_METHOD	artificial intelligence
This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project	178	194	ANALYTICAL_METHOD	machine learning
We set out to determine whether machine learning-based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD)	32	54	ANALYTICAL_METHOD	machine learning-based
These results demonstrate that machine learning can achieve accurate and, importantly, replicable prediction of SSRI therapy response using total baseline depression severity combined with pharmacogenomic biomarkers	31	47	ANALYTICAL_METHOD	machine learning
Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning	161	184	ANALYTICAL_METHOD	artificial intelligence
Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning	189	205	ANALYTICAL_METHOD	machine learning
We demonstrate that deep neural networks outperform the current state in machine learning frameworks	20	40	ANALYTICAL_METHOD	deep neural networks
We demonstrate that deep neural networks outperform the current state in machine learning frameworks	73	89	ANALYTICAL_METHOD	machine learning
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	182	215	ANALYTICAL_METHOD	non-negative matrix factorization
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	223	244	ANALYTICAL_METHOD	partial least squares
A way to generate predictive models for the remaining cases is with suitable machine learning algorithms that are yet to be applied to existing in vitro pharmacogenomics datasets	77	93	ANALYTICAL_METHOD	machine learning
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	15	31	ANALYTICAL_METHOD	machine learning
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	54	65	ANALYTICAL_METHOD	naive Bayes
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	83	105	ANALYTICAL_METHOD	support vector machine
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	113	135	ANALYTICAL_METHOD	elastic net regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	144	163	ANALYTICAL_METHOD	logistic regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	170	186	ANALYTICAL_METHOD	lasso regression
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	194	234	ANALYTICAL_METHOD	multivariate adaptive regression splines
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	243	266	ANALYTICAL_METHOD	boosted regression tree
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	277	290	ANALYTICAL_METHOD	random forest
The capability of learning representations from structures directly without using any predefined structure descriptor is an important feature distinguishing deep learning from other machine learning methods and makes the traditional feature selection and reduction procedures unnecessary	182	198	ANALYTICAL_METHOD	machine learning
In the wake of recent advances in machine learning research, the study of pharmacogenomics using predictive algorithms serves as a new paradigmatic application	34	50	ANALYTICAL_METHOD	machine learning
In this work, our goal was to explore an ensemble machine learning approach which aims to predict probable antidepressant treatment response and remission in major depressive disorder (MDD)	41	66	ANALYTICAL_METHOD	ensemble machine learning
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	30	46	ANALYTICAL_METHOD	machine learning
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	102	141	ANALYTICAL_METHOD	multi-layer feedforward neural networks
Many machine learning techniques have been demonstrated in this domain	5	21	ANALYTICAL_METHOD	machine learning
Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning	227	238	ANALYTICAL_METHOD	data mining
Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning	243	259	ANALYTICAL_METHOD	machine learning
Furthermore, we performed a machine learning analysis and determined that Native American admixture and heart failure were strongly predictive of AF in PHR	28	44	ANALYTICAL_METHOD	machine learning
Here, we leverage publicly available, whole genome sequencing data collected from global populations, evolutionary characteristics, and annotated protein features to construct a new in silico machine learning pharmacogenetic identification method called XGB-PGX	192	208	ANALYTICAL_METHOD	machine learning
We used the anti-epileptic drug brivaracetam as a case study and combine a hybrid data/knowledge-driven feature extraction with machine learning to systematically integrate clinical and genetic data from a clinical discovery dataset (n\u2009=\u2009235 patients)	128	144	ANALYTICAL_METHOD	machine learning
Hence, it provides a blueprint for how machine learning-based multimodal data integration can act as a driver in achieving the goals of precision medicine in fields such as neurology	39	61	ANALYTICAL_METHOD	machine learning-based
Five machine learning algorithms combined with four resampling techniques were used to build optimal predictive model	5	21	ANALYTICAL_METHOD	machine learning
By machine learning, we have developed and validated comprehensive models to predict the risk of neutropenia and fever	3	19	ANALYTICAL_METHOD	machine learning
This study assesses the value of potentially functional single nucleotide polymorphisms (pfSNPs) and employs six machine learning algorithms to identify the combination of SNPs that best predict myalgia	113	129	ANALYTICAL_METHOD	machine learning
Variants that were highly associated with myalgia from this and previous studies were extracted, assessed for potential functionality (pfSNPs) and incorporated into six machine learning models	169	185	ANALYTICAL_METHOD	machine learning
The minimum combination of SNPs to achieve maximum sensitivity and specificity as determined by AUC, that predict atorvastatin-induced myalgia in most, if not all the six machine learning models was determined	171	187	ANALYTICAL_METHOD	machine learning
pfSNPs were found to be more robust in predicting myalgia, outperforming non-pf SNPs in the majority of machine learning models tested	104	120	ANALYTICAL_METHOD	machine learning
<b>Conclusion:</b> Combinations of pfSNPs that were consistently identified by different machine learning models to have high predictive performance have good potential to be clinically useful for predicting atorvastatin-induced myalgia once validated against an independent cohort of patients	89	105	ANALYTICAL_METHOD	machine learning
This work proposes a machine learning approach to infer robust predictors of drug responses from patient genomic information	21	37	ANALYTICAL_METHOD	machine learning
Graph structures have received increasing attention owing to their outstanding performance in machine learning	94	110	ANALYTICAL_METHOD	machine learning
This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning	177	193	ANALYTICAL_METHOD	machine learning
Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5	34	53	ANALYTICAL_METHOD	cart classification
Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5	5	21	ANALYTICAL_METHOD	machine learning
Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5	58	74	ANALYTICAL_METHOD	regression trees
When developed machine learning models were evaluated in the validation dataset, the C5	15	31	ANALYTICAL_METHOD	machine learning
In addition, we preliminarily explored the machine learning-based methods for identifying mutation markers of anti-cancer drug sensitivity and produced optimistic results, which suggests that a reliable dataset may provide new insights and essential clues for future cancer pharmacogenomics studies	43	65	ANALYTICAL_METHOD	machine learning-based
Machine learning methods have been employed to predict drug sensitivity based on the multiple omics data available for large panels of cancer cell lines	0	16	ANALYTICAL_METHOD	Machine learning
However, there are no comprehensive guidelines on how to properly train and validate such machine learning models for drug sensitivity prediction	90	106	ANALYTICAL_METHOD	machine learning
However, there is no evidence that machine learning approaches combining multi-omics measures (e	35	51	ANALYTICAL_METHOD	machine learning
Machine Learning (ML) is emerging as a particularly promising complementary approach to precision oncology	0	16	ANALYTICAL_METHOD	Machine Learning
We compare the accuracy of stable warfarin dose prediction using linear and nonlinear machine learning models in a large cohort enriched for US Latinos and Latin Americans (ULLA)	76	102	ANALYTICAL_METHOD	nonlinear machine learning
Our tool also includes a machine learning random forest binary classifier that showed an accuracy of 73%	25	73	ANALYTICAL_METHOD	machine learning random forest binary classifier
To identify the parameters that had the greatest importance for the prediction of the therapy response to metformin, we next built a set of machine learning models, based on the various combinations of genetic and phenotypic characteristics	140	156	ANALYTICAL_METHOD	machine learning
Using machine learning (ML) techniques with pharmacogenomics data provides one pathway toward individualized prediction of therapeutic outcomes of antidepressants	6	22	ANALYTICAL_METHOD	machine learning
Extensive in vitro cancer drug screening datasets have enabled scientists to identify biomarkers and develop machine learning models for predicting drug sensitivity	109	125	ANALYTICAL_METHOD	machine learning
CREAMMIST provides easy-to-use statistics derived from the integrative dose-response curves for various downstream analyses such as identifying biomarkers, selecting drug concentrations for experiments, and training robust machine learning models	223	239	ANALYTICAL_METHOD	machine learning
To overcome this hurdle, machine learning models have been extensively adapted in drug dose prediction	25	41	ANALYTICAL_METHOD	machine learning
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	48	64	ANALYTICAL_METHOD	machine learning
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	77	88	ANALYTICAL_METHOD	Elastic Net
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	90	95	ANALYTICAL_METHOD	LASSO
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	101	106	ANALYTICAL_METHOD	Ridge
Based on the concept of precision pharmacy, we adpoted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children and elderly patients	152	168	ANALYTICAL_METHOD	machine learning
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	31	38	ANALYTICAL_METHOD	Firefly
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	43	65	ANALYTICAL_METHOD	Grey Wolf Optimization
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	133	149	ANALYTICAL_METHOD	Machine Learning
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	172	190	ANALYTICAL_METHOD	Stacking Algorithm
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	209	251	ANALYTICAL_METHOD	Convolutional Temporal Deep Neural Network
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	255	260	ANALYTICAL_METHOD	CTDN
Based on these findings, data from patients treated with cannabis and genotyped for several candidate polymorphic genes (single-nucleotide polymorphism: SNP) were collected, integrated, and analyzed through a machine learning (ML) model to demonstrate that the reduction in pain intensity is closely related to gene polymorphisms	209	225	ANALYTICAL_METHOD	machine learning
Genome-wide patterns of pharmacogenomic variation-6311 drug response-associated variants for <i>All of Us</i> and 5966 variants for <i>UKB</i>-were analyzed with machine learning classifiers to predict participants' self-identified race and ethnicity	162	178	ANALYTICAL_METHOD	machine learning
Based on the concept of precision pharmacy, we adopted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children, and elderly patients	152	168	ANALYTICAL_METHOD	machine learning
A machine learning classifier method was used to discover classification rules for our dataset	2	18	ANALYTICAL_METHOD	machine learning
PANCDR outperformed other machine learning models in predicting external test data	0	6	ANALYTICAL_METHOD	PANCDR
PANCDR outperformed other machine learning models in predicting external test data	26	42	ANALYTICAL_METHOD	machine learning
Data science and machine learning play a crucial role in the processing and interpretation of results, using enormous databases and statistics to discover new and support current genotype-phenotype correlations	17	33	ANALYTICAL_METHOD	machine learning
A machine learning model was trained to predict the genome-wide chromatin accessibility from transcriptome data using the paired expression and chromatin accessibility data collected from ENCODE and ROADMAP	2	18	ANALYTICAL_METHOD	machine learning
An area of recent interest is the potential for machine learning (ML) applications within pharmacology	48	64	ANALYTICAL_METHOD	machine learning
Two signatures for prognosis and EGFRi sensitivity were developed via machine learning	70	86	ANALYTICAL_METHOD	machine learning
This study investigates how artificial intelligence (AI) and machine learning (ML) can address key challenges in integrating pharmacogenomics (PGx) into psychiatric care	61	77	ANALYTICAL_METHOD	machine learning
(Genetics 1987; 117:343-351) and hierarchical clustering of haplotypes as described by Durrant et al	33	56	ANALYTICAL_METHOD	hierarchical clustering
Results: Using unsupervised hierarchical clustering and a combination of candidate genotypes and clinical variables, we identified several distinct clusters of patients at high risk (36-38%) and low risk (10-17%) of respiratory depression; the relative risk of respiratory depression for high versus low risk clusters was 2	15	51	ANALYTICAL_METHOD	unsupervised hierarchical clustering
Hierarchical clustering of the common genes represented in both mRNA and protein datasets displayed two dominant patterns	0	23	ANALYTICAL_METHOD	Hierarchical clustering
Identification of groups of features is performed by hierarchical clustering	53	76	ANALYTICAL_METHOD	hierarchical clustering
This chapter presents a workflow to interrogate multiple genomic inputs and individually assess their relationship with the phenotype of drug resistance using hierarchical clustering to determine the set of features that can best describe what features are associated with drug resistance	159	182	ANALYTICAL_METHOD	hierarchical clustering
Finally, structural analysis and molecular dynamics simulation indicated that TPMT*27 was less stable than was the wild type TPMT allozyme	33	51	ANALYTICAL_METHOD	molecular dynamics
We used molecular dynamics (MD) simulation to predict the structure of the complex of human TPMT-AdoHcy(CH(2))6MP, where the sulfur atoms of AdoHcy and 6MP were linked by a CH(2) group	8	26	ANALYTICAL_METHOD	molecular dynamics
Molecular dynamics simulation (MDS) approach was conducted to investigate conformational changes in the mutant protein structure with respect to its native conformation	0	18	ANALYTICAL_METHOD	Molecular dynamics
The bfPGRP1-ligand complex molecular dynamics simulation followed by free binding energy (BE) computation conceded BE values of -18	27	45	ANALYTICAL_METHOD	molecular dynamics
We had applied molecular dynamics simulation to study the possible conformational changes induced by Lys256Arg transversion on the overall structure of integrin and we have analyzed the binding affinities of natalizumab in the non-mutated and mutated structures through HINT score	15	33	ANALYTICAL_METHOD	molecular dynamics
In order to address this issue, we developed a computational pipeline of vitamin D receptor (VDR) for SNP centered study by application of elegant molecular docking and molecular dynamics simulation approaches	147	164	ANALYTICAL_METHOD	molecular docking
In order to address this issue, we developed a computational pipeline of vitamin D receptor (VDR) for SNP centered study by application of elegant molecular docking and molecular dynamics simulation approaches	169	187	ANALYTICAL_METHOD	molecular dynamics
Gly187Trp mutant embedded in different lipid bilayers and relaxed them for hundreds of nanoseconds by molecular dynamics simulations	102	120	ANALYTICAL_METHOD	molecular dynamics
Molecular dynamics results validated the stable conformation of oridonin docking pose on Akt kinase domain	0	18	ANALYTICAL_METHOD	Molecular dynamics
Further, the mutant displayed enhanced structural flexibility particularly in the low density lipoprotein (LDL) binding domain, decreased solvent accessibility of catalytic residues-Phe274 and Ser273 and increased C\u0251 distance between Phe274 and Leu153 and large conformational entropy change as inferred from all-atom molecular dynamics (MD) simulation and essential dynamics (ED) studies	318	341	ANALYTICAL_METHOD	atom molecular dynamics
Further, the effect of amino acid substitutions CYP2C9 variants on the protein flexibility in the presence of tamoxifen in 4-hydroxy orientation was evaluated by molecular dynamics (MD) simulations	162	180	ANALYTICAL_METHOD	molecular dynamics
Besides, the influence of rs1065852 on the structure of CYP2D6 was further investigated via molecular dynamics simulations	92	110	ANALYTICAL_METHOD	molecular dynamics
Molecular dynamics simulations revealed higher overall flexibility, decreased intramolecular hydrogen bonds and lower content of regular secondary structures for both cancer driver variants G73W and F432S when compared to the wild-type structure	0	18	ANALYTICAL_METHOD	Molecular dynamics
We previously proposed combining molecular dynamics (MD) and dynamic residue network (DRN) analysis to decipher the molecular mechanisms of missense mutations in other proteins	33	51	ANALYTICAL_METHOD	molecular dynamics
We previously proposed combining molecular dynamics (MD) and dynamic residue network (DRN) analysis to decipher the molecular mechanisms of missense mutations in other proteins	61	84	ANALYTICAL_METHOD	dynamic residue network
Five missense variants were modeled and microsecond scale molecular dynamics simulations were conducted for each, as well as for the CYP3A5 wildtype and the Y53C variant, which has a known deleterious impact on enzyme activity	58	76	ANALYTICAL_METHOD	molecular dynamics
Here we have evaluated spatio-temporal functional and molecular dynamics of five PDO models established after hepatic re-resections and neoadjuvant combination chemotherapies in a patient with microsatellite stable and KRAS mutated metastatic rectal cancer	54	72	ANALYTICAL_METHOD	molecular dynamics
We show how computational approaches such as bioinformatics tools and molecular dynamics simulations can be used to characterize the variant receptors in comparison to the wildtype receptor	70	88	ANALYTICAL_METHOD	molecular dynamics
Moreover, the stability behavior of selected docked complexes (drugs-EWS) was checked by molecular dynamics simulations	89	107	ANALYTICAL_METHOD	molecular dynamics
Finally, molecular dynamics simulations were used to investigate the stability of the best selected docked complexes	9	27	ANALYTICAL_METHOD	molecular dynamics
Further, the molecular dynamics simulations were performed to comprehend the conformational changes and stability of the targets upon binding of the selected top ranked RA drug	13	31	ANALYTICAL_METHOD	molecular dynamics
As a result, the five best flavonoid-docked complexes were selected and further evaluated by Molecular Dynamics (MD) simulation studies at 100 ns	93	111	ANALYTICAL_METHOD	Molecular Dynamics
<b>Results:</b> Normal mode analysis and molecular dynamics highlight the effects of known CYP missense variants on protein stability and conformational dynamics	41	59	ANALYTICAL_METHOD	molecular dynamics
Molecular dynamics simulations revealed large conformational fluctuations, confirming the predicted reduced function of <i>*86</i> and <i>*113</i> alleles	0	18	ANALYTICAL_METHOD	Molecular dynamics
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	68	85	ANALYTICAL_METHOD	molecular-network
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	110	121	ANALYTICAL_METHOD	text-mining
The progress of molecular biology with particular consideration of genotyping and DNA microarray technologies has created a basis for the dynamic progress of pharmacogenetics, allowing fast and sensitive determination of the individual pharmacogenetic profile, encompassing a large set of CYP alleles extended by allelic variants of genes encoding other enzymes participating in drug metabolism	82	96	ANALYTICAL_METHOD	DNA microarray
Microarray-based mRNA expression profiling, COMPARE, and hierarchical cluster analyses were applied to identify which genes correlate with sensitivity or resistance to selected phytochemicals of the Korean plants	57	77	ANALYTICAL_METHOD	hierarchical cluster
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel	42	71	ANALYTICAL_METHOD	hierarchical cluster analyses
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	16	50	ANALYTICAL_METHOD	expression quantitative trait loci
DNA-binding motif analysis of the microarray-retrieved deregulated genes in the promoter region revealed NF\u03baB as potential transcription factor involved in cryptotanshinone's mode of action	0	17	ANALYTICAL_METHOD	DNA-binding motif
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	62	75	ANALYTICAL_METHOD	Linear Models
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	127	140	ANALYTICAL_METHOD	Decision Tree
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	145	158	ANALYTICAL_METHOD	Random Forest
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	159	175	ANALYTICAL_METHOD	machine learning
To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts	163	194	ANALYTICAL_METHOD	genome-wide association studies
Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	56	89	ANALYTICAL_METHOD	Multivariable logistic regression
Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	363	393	ANALYTICAL_METHOD	Univariate logistic regression
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	124	139	ANALYTICAL_METHOD	gene expression
A Cox proportional hazards model was utilized to assess the impact of genetic markers on survival outcomes.	2	32	ANALYTICAL_METHOD	Cox proportional hazards model
A generalized linear model (GLM) framework was employed to analyze the association between genetic variants and drug response.	2	26	ANALYTICAL_METHOD	generalized linear model
A mixed-effects model was used to account for both fixed and random effects in the pharmacogenomic analysis.	2	21	ANALYTICAL_METHOD	mixed-effects model
A support vector machine (SVM) was utilized to classify patients based on their pharmacogenomic data.	2	24	ANALYTICAL_METHOD	support vector machine
Bayesian network modeling was employed to understand the probabilistic relationships between genetic variants and drug response.	0	25	ANALYTICAL_METHOD	Bayesian network modeling
Canonical correlation analysis (CCA) was performed to explore the relationships between genetic and clinical variables.	0	30	ANALYTICAL_METHOD	Canonical correlation analysis
Causal inference methods were used to distinguish direct effects of genetic variants on drug response from indirect effects.	0	24	ANALYTICAL_METHOD	Causal inference methods
Conditional logistic regression was used to analyze matched case-control pharmacogenomic data.	12	31	ANALYTICAL_METHOD	logistic regression
Functional studies in silico, such as molecular docking, molecular dynamics, and conformational analysis, will be used to explore the impact of novel variants on protein structure and function	81	104	ANALYTICAL_METHOD	conformational analysis
Functional studies in silico, such as molecular docking, molecular dynamics, and conformational analysis, will be used to explore the impact of novel variants on protein structure and function	38	55	ANALYTICAL_METHOD	molecular docking
Functional studies in silico, such as molecular docking, molecular dynamics, and conformational analysis, will be used to explore the impact of novel variants on protein structure and function	57	75	ANALYTICAL_METHOD	molecular dynamics
Gene set enrichment analysis (GSEA) was conducted to identify gene sets significantly associated with drug response.	0	28	ANALYTICAL_METHOD	Gene set enrichment analysis
Genome-wide association studies (GWAS) were performed using PLINK software to identify significant SNPs.	0	31	ANALYTICAL_METHOD	Genome-wide association studies
Hidden Markov models (HMM) were used to detect regions of the genome associated with drug response.	0	20	ANALYTICAL_METHOD	Hidden Markov models
Hierarchical clustering was used to group patients based on their pharmacogenomic profiles.	0	23	ANALYTICAL_METHOD	Hierarchical clustering
Kaplan-Meier survival analysis was conducted to compare outcomes between different genotype groups.	0	30	ANALYTICAL_METHOD	Kaplan-Meier survival analysis
Linear discriminant analysis (LDA) was employed to distinguish between responders and non-responders to treatment.	0	28	ANALYTICAL_METHOD	Linear discriminant analysis
machine learning techniques to assess treatment prediction, prognosis prediction, diagnosis prediction, and the detection of potential biomarkers	0	27	ANALYTICAL_METHOD	machine learning techniques
Mendelian randomization analysis was used to infer causal relationships between genetic variants and drug efficacy.	0	32	ANALYTICAL_METHOD	Mendelian randomization analysis
Multivariable logistic regression models were fitted to assess the impact of multiple genetic and clinical factors.	0	40	ANALYTICAL_METHOD	Multivariable logistic regression models
Multivariate adaptive regression splines (MARS) were used to model nonlinear relationships in pharmacogenomic data.	0	40	ANALYTICAL_METHOD	Multivariate adaptive regression splines
Multivariate analysis of variance (MANOVA) was used to examine the interaction between multiple genetic factors and drug efficacy.	0	33	ANALYTICAL_METHOD	Multivariate analysis of variance
Network-based approaches were used to construct and analyze gene-gene interaction networks in pharmacogenomics.	0	24	ANALYTICAL_METHOD	Network-based approaches
Partial correlation analysis was performed to account for confounding variables in the genetic association study.	0	28	ANALYTICAL_METHOD	Partial correlation analysis
Partial least squares (PLS) regression was employed to model the relationship between genetic markers and drug efficacy.	0	21	ANALYTICAL_METHOD	Partial least squares
Pathway enrichment analysis was conducted using DAVID to identify biological pathways affected by genetic variants.	0	27	ANALYTICAL_METHOD	Pathway enrichment analysis
Pathway-based analysis was conducted to integrate genetic data with known drug metabolism pathways.	0	22	ANALYTICAL_METHOD	Pathway-based analysis
Permutation-based significance testing was used to validate the robustness of the pharmacogenomic findings.	0	38	ANALYTICAL_METHOD	Permutation-based significance testing
Principal component analysis (PCA) was conducted to reduce the dimensionality of the pharmacogenomic data.	0	28	ANALYTICAL_METHOD	Principal component analysis
Quantitative trait locus (QTL) mapping was conducted to identify loci associated with drug response traits.	0	24	ANALYTICAL_METHOD	Quantitative trait locus
Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive accuracy of pharmacogenomic models.	0	33	ANALYTICAL_METHOD	Receiver operating characteristic
Survival analysis using the log-rank test was performed to compare time-to-event outcomes between genotypes.	0	17	ANALYTICAL_METHOD	Survival analysis
The LASSO (least absolute shrinkage and selection operator) method was used to select relevant genetic predictors.	4	9	ANALYTICAL_METHOD	LASSO
The Markov Chain Monte Carlo (MCMC) method was used for Bayesian inference in pharmacogenomic models.	0	28	ANALYTICAL_METHOD	The Markov Chain Monte Carlo
The study applied Fisher's exact test to determine the association between genetic variants and adverse drug reactions.	18	37	ANALYTICAL_METHOD	Fisher's exact test
The study applied stepwise regression techniques to select the most predictive genetic variables.	18	48	ANALYTICAL_METHOD	stepwise regression techniques
The study employed decision tree algorithms to develop clinical decision support tools based on pharmacogenomic data.	19	43	ANALYTICAL_METHOD	decision tree algorithms
The study employed elastic net regression to integrate genetic and clinical data for predicting drug response.	19	41	ANALYTICAL_METHOD	elastic net regression
The study employed machine learning algorithms, including random forests, to predict drug response based on genetic data.	19	46	ANALYTICAL_METHOD	machine learning algorithms
The study employed structural equation modeling (SEM) to explore complex relationships between genetic and phenotypic variables.	19	47	ANALYTICAL_METHOD	structural equation modeling
The study used a sliding window approach to perform regional association tests in the genome.	17	40	ANALYTICAL_METHOD	sliding window approach
The study used k-means clustering to identify subgroups of patients with similar pharmacogenomic profiles.	15	33	ANALYTICAL_METHOD	k-means clustering
The study used Monte Carlo simulations to assess the uncertainty in pharmacogenomic predictions.	15	38	ANALYTICAL_METHOD	Monte Carlo simulations
The study used the Bonferroni correction method to adjust for multiple testing in GWAS.	19	47	ANALYTICAL_METHOD	Bonferroni correction method
The study used the False Discovery Rate (FDR) approach to control for type I errors in multiple comparisons.	19	39	ANALYTICAL_METHOD	False Discovery Rate
The study used the Wilcoxon rank-sum test to compare genetic variant frequencies between case and control groups.	19	41	ANALYTICAL_METHOD	Wilcoxon rank-sum test
The study utilized permutation testing to assess the significance of the observed associations.	19	38	ANALYTICAL_METHOD	permutation testing
This work proposes a machine learning approach to infer robust predictors of drug responses from patient genomic information	21	46	ANALYTICAL_METHOD	machine learning approach
We applied logistic regression analysis to identify genetic variants associated with drug response.	11	30	ANALYTICAL_METHOD	logistic regression
we have provided a brief overview of the possibilities of implementing CNNs as an effective tool for analyzing one-dimensional biological data	71	75	ANALYTICAL_METHOD	CNNs
we introduce an elastic-net regression methodology to compare a drug-cell line pair against an alternative pair	16	38	ANALYTICAL_METHOD	elastic-net regression
We propose to apply the principles artificial intelligence to develop a medication optimization platform to prevent, manage and treat different diseases	35	58	ANALYTICAL_METHOD	artificial intelligence
Here we present a novel machine-learning method called REGENIE for fitting a whole-genome regression model for quantitative and binary phenotypes that is substantially faster than alternatives in multi-trait analyses while maintaining statistical efficiency	24	40	ANALYTICAL_METHOD	machine-learning
Here we present a novel machine-learning method called REGENIE for fitting a whole-genome regression model for quantitative and binary phenotypes that is substantially faster than alternatives in multi-trait analyses while maintaining statistical efficiency	90	106	ANALYTICAL_METHOD	regression model
We explore the role of the prior distribution in whole-genome regression models for dissecting complex traits in what is now a standard situation with genomic data	62	79	ANALYTICAL_METHOD	regression models
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine.	58	81	ANALYTICAL_METHOD	artificial intelligence
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine.	92	108	ANALYTICAL_METHOD	machine learning
in silico and large-scale functional assessment of rare variant effects on protein function are at the forefront of pharmacogenetic research to facilitate their clinical integration.	0	9	ANALYTICAL_METHOD	in silico
We propose to apply the principles artificial intelligence to develop a medication optimization platform to prevent, manage and treat different diseases.	35	58	ANALYTICAL_METHOD	artificial intelligence
The field of pharmacogenomics, comprising pharmacokinetics (PK) and pharmacodynamics (PD), has been revolutionized by computer-aided drug design (CADD) and structure-based drug design (SBDD).	156	183	ANALYTICAL_METHOD	structure-based drug design
These developments are paralleled by advances in machine learning, which have allowed us to parse the immense wealth of data and establish novel genetic markers and polygenic models for drug selection and dosing.	49	65	ANALYTICAL_METHOD	machine learning
We then annotated variant call format (VCF) files using Golden Helix VarSeq 2.5.0 and employed Stargazer v2.0.2 for star allele analysis.	56	75	ANALYTICAL_METHOD	Golden Helix VarSeq
the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs.	110	114	ANALYTICAL_METHOD	GWAS
Potential explanations for low replication rate include differences in microarray platforms, statistical modeling, covariates considered and origin and collection procedures of tissues	93	113	ANALYTICAL_METHOD	statistical modeling
However, different study designs would be needed to examine common variation with minor effect sizes, or rare variation, influencing AED or LEV response or epilepsy predisposition	60	100	CHALLENGE	common variation with minor effect sizes
However, different study designs would be needed to examine common variation with minor effect sizes, or rare variation, influencing AED or LEV response or epilepsy predisposition	105	119	CHALLENGE	rare variation
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	5	19	CHALLENGE	cost-effective
Strategies for detecting and interpreting rare variation will be critical for enabling broad application of pharmacogenetics	15	56	CHALLENGE	detecting and interpreting rare variation
Delivery of proteins and peptides presents special challenges	0	33	CHALLENGE	Delivery of proteins and peptides
Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries	93	131	CHALLENGE	the very richness of the clinical data
Genomic variation among individuals and populations is a new factor that enriches and challenges our understanding of these complex relationships	0	51	CHALLENGE	Genomic variation among individuals and populations
Variable warfarin response during treatment initiation poses a significant challenge to providing optimal anticoagulation therapy	0	26	CHALLENGE	Variable warfarin response
The challenge remains therefore, to develop more effective systemic therapies against this challenging malignancy	36	77	CHALLENGE	develop more effective systemic therapies
Despite major advancements in therapeutics, variability in drug response remains a challenge in both adults and children diagnosed with rheumatic disease	44	72	CHALLENGE	variability in drug response
Additionally, we discuss the major challenges in translating this knowledge into a systems-level understanding of drug physiology, with the ultimate goal of developing more effective personalized clinical treatment strategies	49	110	CHALLENGE	translating this knowledge into a systems-level understanding
This article will discuss the issues involved in mobilizing a PGx study during the conduct of a clinical trial, including the development of a PGx hypothesis, the identification of genetic markers for analysis, PGx platform selection and assay development, as well as challenges that arise in relation to global laws and regulations related to genetic research and logistical/timeline concerns in the execution of a PGx analysis	321	360	CHALLENGE	regulations related to genetic research
This article will discuss the issues involved in mobilizing a PGx study during the conduct of a clinical trial, including the development of a PGx hypothesis, the identification of genetic markers for analysis, PGx platform selection and assay development, as well as challenges that arise in relation to global laws and regulations related to genetic research and logistical/timeline concerns in the execution of a PGx analysis	305	316	CHALLENGE	global laws
In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union	280	302	CHALLENGE	regulatory perspective
Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies	0	19	CHALLENGE	Incidental findings
Focusing on the challenges of the incidentalome, the large set of incidental findings potentially generated through genotyping, the paper argues that provisional approaches to managing incidental findings may be implemented if necessary to allow benefits of pharmacogenomic testing to be realized in the clinical setting	34	47	CHALLENGE	incidentalome
In this paper, we describe studies being conducted within the eMERGE network to develop best practices for integrating genomic findings into the EHR, and the challenges associated with such work	107	148	CHALLENGE	integrating genomic findings into the EHR
While such cases may be rare, the clinical/genetic testing community must be aware of the challenges of CYP2D6 testing on the AmpliChip platform and implications regarding accuracy of test results	104	144	CHALLENGE	CYP2D6 testing on the AmpliChip platform
However, the challenge now in using chemotherapy to treat nonsmall-cell lung cancer is to identify more molecular markers predictive of drug sensitivity and determine the optimal drug sequences in order to tailor treatment to each patient	30	48	CHALLENGE	using chemotherapy
Previous literature has established theoretical models for PGx CDS implementation and discussed a number of anticipated real-world challenges	120	141	CHALLENGE	real-world challenges
Anticipated challenges include data storage and management, system integration, physician acceptance, and more	31	58	CHALLENGE	data storage and management
Anticipated challenges include data storage and management, system integration, physician acceptance, and more	60	78	CHALLENGE	system integration
Anticipated challenges include data storage and management, system integration, physician acceptance, and more	80	100	CHALLENGE	physician acceptance
The next-generation sequencing platforms generate huge amounts of genetic variation data and it remains a challenge to interpret the variations that are identified	66	88	CHALLENGE	genetic variation data
Inevitably, this leads to increased diagnostic delays and challenges in the interpretation of genetic variants	76	110	CHALLENGE	interpretation of genetic variants
Nowadays, we are experiencing the big data era with the emerging challenge of single data interpretation	78	104	CHALLENGE	single data interpretation
Implementation challenges include the limited evidence base available to guide clinical use and the lack of data from diverse populations	38	59	CHALLENGE	limited evidence base
Panel-based next generation sequencing (NGS) is currently preferred over whole exome sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by variants of uncertain clinical significance (VUS)	150	164	CHALLENGE	interpretation
A formidable challenge is successfully integrating pharmacogenomic information into clinical practice	39	101	CHALLENGE	integrating pharmacogenomic information into clinical practice
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	28	56	CHALLENGE	selecting a testing platform
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	58	84	CHALLENGE	communicating test results
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	86	130	CHALLENGE	building clinical decision support processes
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	132	172	CHALLENGE	providing patient and provider education
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	178	266	CHALLENGE	integrating methods to support the translation of emerging evidence to clinical practice
This article argues that increased pharmacogenetics education and system-wide implementation is necessary to overcome some of these challenges	25	61	CHALLENGE	increased pharmacogenetics education
However, efficient delivery of this information to the point of prescribing remains a significant challenge	9	47	CHALLENGE	efficient delivery of this information
The field of pharmacogenomics presents great challenges for researchers that are willing to make their studies reproducible and shareable	4	29	CHALLENGE	field of pharmacogenomics
Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression	0	21	CHALLENGE	Psychiatric disorders
Here, we detail successes, challenges, and recent advances in fibrate pharmacogenomics	62	86	CHALLENGE	fibrate pharmacogenomics
Here, we provide an overview of considerations made to mitigate multiple methodological challenges that emerged during the design	64	87	CHALLENGE	multiple methodological
Potential novel genetic treatment modalities are challenged but still in the early phase of the investigation	0	44	CHALLENGE	Potential novel genetic treatment modalities
The issues and challenges in the diagnosis of drug allergy/hypersensitivity among children and adults in Asia are likely to be different from non-Asian countries	33	75	CHALLENGE	diagnosis of drug allergy/hypersensitivity
In this response article, we challenge a core assumption that lies at the centre of a round table discussion regarding the Pharmacogenetics to Avoid Loss of Hearing trial	125	172	CHALLENGE	armacogenetics to Avoid Loss of Hearing trial
Major challenges to widescale implementation of PGx include lack of physician experience or confidence in interpreting the data	60	88	CHALLENGE	lack of physician experience
Major challenges to widescale implementation of PGx include lack of physician experience or confidence in interpreting the data	92	127	CHALLENGE	confidence in interpreting the data
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	25	88	CHALLENGE	adapting to a constantly changing global regulatory environment
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	90	116	CHALLENGE	challenges in study design
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	121	144	CHALLENGE	clinical implementation
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	154	194	CHALLENGE	increasing concerns over patient privacy
The development of chronic kidney disease (CKD) drugs remains a challenge due to the variations in the genes	0	53	CHALLENGE	The development of chronic kidney disease (CKD) drugs
However, challenges remain and are hindering the widespread implementation of TDM in clinical practice	49	104	CHALLENGE	widespread implementation of TDM in clinical practice
The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs	4	46	CHALLENGE	implementation of genotyping in the clinic
Precision medication of psychiatric disorders faces challenges in pharmacogenetics and pharmacodynamics research due to difficulties in recruiting human subjects because of possibility of substance abuse and relatively small sample sizes	136	161	CHALLENGE	recruiting human subjects
Despite the introduction of targeted agents leading to therapeutic advances, clinical management of patients with metastatic colorectal cancer (mCRC) is still challenged by significant interindividual variability in treatment outcomes, both in terms of toxicity and therapy efficacy	173	234	CHALLENGE	significant interindividual variability in treatment outcomes
These make the management of such patients a challenge	15	42	CHALLENGE	management of such patients
The implementation of genotyping for anti-hypertensive drugs in clinical practice remains a challenge	4	81	CHALLENGE	implementation of genotyping for anti-hypertensive drugs in clinical practice
This dependence on intracellular activation presents novel challenges for the discovery and development of nucleoside/nucleotide analog drugs	5	43	CHALLENGE	dependence on intracellular activation
To circumvent these challenges, deep neural models are increasingly used to improve the precision and accuracy of warfarin dose predictions	114	139	CHALLENGE	warfarin dose predictions
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	29	43	CHALLENGE	implementation
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	64	97	CHALLENGE	delivery into health-care systems
In recent decades, OS treatment has reached a plateau and drug resistance is still a major challenge	58	73	CHALLENGE	drug resistance
Choosing the most effective chemotherapeutic agent with safest side effect profile is a common challenge in\u00a0cancer treatment	0	50	CHALLENGE	Choosing the most effective chemotherapeutic agent
The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education	128	133	CHALLENGE	scale
The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education	135	146	CHALLENGE	informatics
The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education	152	161	CHALLENGE	education
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges	0	48	CHALLENGE	Drug-induced liver injury (DILI) risk prediction
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges	50	73	CHALLENGE	diagnosis establishment
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges	75	94	CHALLENGE	clinical management
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	74	79	CHALLENGE	costs
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	81	106	CHALLENGE	site engagement logistics
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	108	133	CHALLENGE	socioeconomic variability
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	135	154	CHALLENGE	patient willingness
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	156	187	CHALLENGE	ethics of placebo interventions
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	189	231	CHALLENGE	cannibalizing the treatment arm population
However, implementing these screening concepts in real-world settings poses challenges	9	60	CHALLENGE	implementing these screening concepts in real-world
The potential applications of these genetic polymorphisms as predictive indicators in clinical practice are explored, as are the challenges associated with their implementation	162	176	CHALLENGE	implementation
Bortezomib-induced neuropathic pain (BINP) poses a challenge in multiple myeloma (MM) treatment	0	35	CHALLENGE	Bortezomib-induced neuropathic pain
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	11	28	CHALLENGE	limited resources
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	30	40	CHALLENGE	high costs
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	42	55	CHALLENGE	long duration
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	61	145	CHALLENGE	low hit-to-lead ratio in the development of pharmacogenetics and computer technology
Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties	68	84	CHALLENGE	scarcity of data
The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye	4	36	CHALLENGE	need to protect informed consent
The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye	41	56	CHALLENGE	confidentiality
The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye	64	79	CHALLENGE	promote justice
However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research	74	123	CHALLENGE	the confidentiality of their personal information
However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research	129	175	CHALLENGE	manner by which research results were utilized
However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research	180	225	CHALLENGE	simply the use of their own DNA for research
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	6	27	CHALLENGE	issues of uncertainty
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	29	36	CHALLENGE	consent
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	38	53	CHALLENGE	confidentiality
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	59	65	CHALLENGE	access
However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality	40	72	CHALLENGE	economical and ethical questions
However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality	90	171	CHALLENGE	further progress in our capacity to interpret and store the personal genomic data
However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality	172	214	CHALLENGE	without compromising their confidentiality
Some of these are related to the research process, for example, confidentiality and informed consent in association with human tissue sampling	64	79	CHALLENGE	confidentiality
Some of these are related to the research process, for example, confidentiality and informed consent in association with human tissue sampling	84	100	CHALLENGE	informed consent
Concerns regarding confidentiality and discrimination were stated	19	34	CHALLENGE	confidentiality
Concerns regarding confidentiality and discrimination were stated	39	53	CHALLENGE	discrimination
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	40	56	CHALLENGE	informed consent
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	61	76	CHALLENGE	confidentiality
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	100	108	CHALLENGE	autonomy
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	110	117	CHALLENGE	justice
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	123	129	CHALLENGE	equity
0% of online news articles mentioned testing confidentiality and privacy protection	45	60	CHALLENGE	confidentiality
0% of online news articles mentioned testing confidentiality and privacy protection	65	83	CHALLENGE	privacy protection
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	34	41	CHALLENGE	privacy
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	43	58	CHALLENGE	confidentiality
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	60	68	CHALLENGE	autonomy
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	70	86	CHALLENGE	informed consent
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	88	112	CHALLENGE	fiduciary responsibility
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	114	121	CHALLENGE	respect
This is an overview of drug delivery systems (DDS), starting with various routes of drug administration	23	50	CHALLENGE	drug delivery systems (DDS)
Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care	35	71	CHALLENGE	complexity of the underlying science
Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care	83	184	CHALLENGE	clinical, economic, and organizational barriers to the effective delivery of personalized health care
Current research should optimise the delivery of this single-agent chemotherapy	37	79	CHALLENGE	delivery of this single-agent chemotherapy
In this age of personalized medicine, genetic and genomic testing is expected to become instrumental in health care delivery, but little is known about its actual implementation in clinical practice	130	198	CHALLENGE	little is known about its actual implementation in clinical practice
Anesthesia providers strive to optimize anesthesia delivery and patient outcomes and to specifically reduce anesthesia-related risks and negative outcomes	31	59	CHALLENGE	optimize anesthesia delivery
Anesthesia providers strive to optimize anesthesia delivery and patient outcomes and to specifically reduce anesthesia-related risks and negative outcomes	101	132	CHALLENGE	reduce anesthesia-related risks
Treatment of acute lymphoblastic leukemia (ALL) in adults remains a challenge, as the delivery of intensive chemotherapeutic regimens in this population is less feasible than it is in the pediatric population	0	47	CHALLENGE	Treatment of acute lymphoblastic leukemia (ALL)
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	82	125	CHALLENGE	the clinical relevance of genomic variation
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	127	171	CHALLENGE	potential variation in technical performance
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	179	202	CHALLENGE	computational analysis;
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	203	242	CHALLENGE	management of massive information sets;
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	247	330	CHALLENGE	must have available clinical interventions that can be informed by genomic analysis
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	338	401	CHALLENGE	to attain more favorable cost management of healthcare delivery
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	406	452	CHALLENGE	demonstrate improvements in cost-effectiveness
Increased knowledge on the role of ethnicity in PD may help shed light on the symptom expression and treatment response of PD, address inequalities in health care delivery worldwide and improve the delivery of personalised medicine	135	171	CHALLENGE	inequalities in health care delivery
Increased knowledge on the role of ethnicity in PD may help shed light on the symptom expression and treatment response of PD, address inequalities in health care delivery worldwide and improve the delivery of personalised medicine	198	232	CHALLENGE	delivery of personalised medicine
Nevertheless, the efficacy of siRNA delivery has, so far, remained a challenging issue	14	44	CHALLENGE	the efficacy of siRNA delivery
This is due to their easy degradation through the circulation system and the difficulties in the intracellular delivery to specific tissues where they silence the target genes	77	119	CHALLENGE	difficulties in the intracellular delivery
However, efficient delivery of this information to the point of prescribing remains a significant challenge	9	47	CHALLENGE	efficient delivery of this information
However, integration of PGx testing may be limited as no uniform approach to delivery of tests has been established and providers are ill-prepared to integrate PGx testing into routine care	54	94	CHALLENGE	no uniform approach to delivery of tests
However, integration of PGx testing may be limited as no uniform approach to delivery of tests has been established and providers are ill-prepared to integrate PGx testing into routine care	120	189	CHALLENGE	providers are ill-prepared to integrate PGx testing into routine care
Pharmacogenomics (PGx) education is crucial to support the effective delivery of PGx services in any health care system	0	32	CHALLENGE	Pharmacogenomics (PGx) education
They provide precision delivery of medications based on knowledge of pharmacogenetics, patient and family education related to the meaning of genomics, health and family assessments, and critical feedback and insights on the feasibility of implementing new technologies into clinical point-of-care or community workflows	225	297	CHALLENGE	feasibility of implementing new technologies into clinical point-of-care
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	64	97	CHALLENGE	delivery into health-care systems
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	170	211	CHALLENGE	massive knowledge gap in pharmacogenomics
The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety	159	173	CHALLENGE	cost-effective
The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety	194	217	CHALLENGE	improving drug efficacy
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	24	58	CHALLENGE	optimal composition of test panels
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	106	134	CHALLENGE	inter-individual variability
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	136	181	CHALLENGE	lack of analytical and quality specifications
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	183	221	CHALLENGE	lack of comprehensive outcome analyses
The incorporation of pharmacogenetic/pharmacogenomic protocols into AD research and clinical practice can foster the optimization of therapeutics by helping to develop cost-effective biopharmaceuticals and improving drug efficacy and safety	160	201	CHALLENGE	develop cost-effective biopharmaceuticals
The incorporation of pharmacogenetic/pharmacogenomic protocols into AD research and clinical practice can foster the optimization of therapeutics by helping to develop cost-effective biopharmaceuticals and improving drug efficacy and safety	206	240	CHALLENGE	improving drug efficacy and safety
This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality	93	110	CHALLENGE	health care costs
alcohol intolerance), (ii) reusable graphical interfaces that reduce extension costs, and (iii) explanations of molecular and cellular drug responses	96	149	CHALLENGE	explanations of molecular and cellular drug responses
alcohol intolerance), (ii) reusable graphical interfaces that reduce extension costs, and (iii) explanations of molecular and cellular drug responses	27	84	CHALLENGE	reusable graphical interfaces that reduce extension costs
The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear	60	106	CHALLENGE	clinical translation of genetic risk estimates
Many existing algorithms do not scale up well for large sequences or databases because of their high-computational costs	28	65	CHALLENGE	not scale up well for large sequences
Many existing algorithms do not scale up well for large sequences or databases because of their high-computational costs	96	120	CHALLENGE	high-computational costs
With the use of molecular criteria and the diminishing cost of analytic technologies, anesthetic practice will become more individualized, and greater emphasis will be placed on the patient's genetic makeup	43	84	CHALLENGE	diminishing cost of analytic technologies
This leads to unnecessarily lengthy processing times and excessive data handling and storage costs	57	80	CHALLENGE	excessive data handling
This leads to unnecessarily lengthy processing times and excessive data handling and storage costs	85	98	CHALLENGE	storage costs
This leads to unnecessarily lengthy processing times and excessive data handling and storage costs	14	46	CHALLENGE	unnecessarily lengthy processing
Clinical trials are ongoing to determine the clinical utility and cost-effectiveness of genotypeguided warfarin dosing	45	61	CHALLENGE	clinical utility
Clinical trials are ongoing to determine the clinical utility and cost-effectiveness of genotypeguided warfarin dosing	66	84	CHALLENGE	cost-effectiveness
Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future	57	87	CHALLENGE	reduction in costs of genomics
The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory	72	81	CHALLENGE	high-cost
The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory	83	97	CHALLENGE	time-consuming
The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory	102	118	CHALLENGE	labour-intensive
It offers high-accuracy, cost-effective and rapid detection	10	23	CHALLENGE	high-accuracy
It offers high-accuracy, cost-effective and rapid detection	25	39	CHALLENGE	cost-effective
It offers high-accuracy, cost-effective and rapid detection	44	59	CHALLENGE	rapid detection
Several models have been proposed to explain the immunopathogenesis of severe T cell-mediated drug HSRs, and our increased understanding of the risk factors and mechanisms involved in the development of these reactions will further the development of sensitive and specific strategies for preclinical screening that will lead to safer and more cost-effective drug design	236	310	CHALLENGE	development of sensitive and specific strategies for preclinical screening
Several models have been proposed to explain the immunopathogenesis of severe T cell-mediated drug HSRs, and our increased understanding of the risk factors and mechanisms involved in the development of these reactions will further the development of sensitive and specific strategies for preclinical screening that will lead to safer and more cost-effective drug design	329	370	CHALLENGE	safer and more cost-effective drug design
This paper argues that pharmacogenomics can complement pharmacologic class effects in drug-safety management, and their use can be implemented without excessive costs or other impracticalities	86	108	CHALLENGE	drug-safety management
This paper argues that pharmacogenomics can complement pharmacologic class effects in drug-safety management, and their use can be implemented without excessive costs or other impracticalities	128	192	CHALLENGE	be implemented without excessive costs or other impracticalities
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	142	176	CHALLENGE	strong drug phenotype associations
Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs	108	155	CHALLENGE	reducing the incidence of adverse drug reaction
Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs	161	181	CHALLENGE	saving medical costs
Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs	79	106	CHALLENGE	reventing medication errors
Precision medicine (also called personalized, stratified, or P4 medicine) can be defined as the tailoring of preventive measures and medical treatments to the characteristics of each patient to obtain the best clinical outcome for each person while ideally also enhancing the cost-effectiveness of such interventions for patients and society	262	294	CHALLENGE	enhancing the cost-effectiveness
This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective	53	103	CHALLENGE	cost-savings in the overall healthcare expenditure
In order for pharmacogenetics to reach its full potential, more cost-effective and easily accessible genotyping methods are desired	83	119	CHALLENGE	easily accessible genotyping methods
In order for pharmacogenetics to reach its full potential, more cost-effective and easily accessible genotyping methods are desired	64	78	CHALLENGE	cost-effective
This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment	81	110	CHALLENGE	reducing adverse side effects
This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment	130	147	CHALLENGE	cost of treatment
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	71	79	CHALLENGE	accurate
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	81	95	CHALLENGE	cost effective
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	100	116	CHALLENGE	rapid genotyping
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	122	163	CHALLENGE	clear guidance on the use of the results
The costs for both kits are not covered by the statutory health insurance and it is therefore proposed that the patients are invoiced directly in the form of individual healthcare payment	28	73	CHALLENGE	not covered by the statutory health insurance
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	92	123	CHALLENGE	rapid and low-cost DNA analysis
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	214	238	CHALLENGE	rapid pathogen detection
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	240	257	CHALLENGE	food traceability
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	262	271	CHALLENGE	forensics
Large-scale epidemiologic studies are required to demonstrate the usefulness and cost-effectiveness of screening tests because their efficacy is affected by the genetic differences among ethnicities	161	198	CHALLENGE	genetic differences among ethnicities
PGx testing that is preemptive, adaptable, current, and executable (PACE) overcomes the human and technological barriers to successful implementation, thus capitalizing on the affordable cost of such testing and clinical practice guidelines at the point of prescription ordering	124	149	CHALLENGE	successful implementation
Logistics and (cost-)effectiveness of pharmacogenetic (PGx)-testing may be optimized when delivered through a pre-emptive panel-based approach, within a clinical decision support system (CDSS)	0	9	CHALLENGE	Logistics
Logistics and (cost-)effectiveness of pharmacogenetic (PGx)-testing may be optimized when delivered through a pre-emptive panel-based approach, within a clinical decision support system (CDSS)	14	34	CHALLENGE	(cost-)effectiveness
This high-throughput low-cost method accurately determines CNV in the CYP2D6 gene enabling reliable estimates of disease prediction in large epidemiological samples	100	164	CHALLENGE	estimates of disease prediction in large epidemiological samples
A sufficiently powered prospective study assessing the (cost-)effectiveness of a panel-based pharmacogenomics approach to guide pharmacotherapy is lacking	55	118	CHALLENGE	(cost-)effectiveness of a panel-based pharmacogenomics approach
Its utility is also challenged by cost and higher reliance on conventional prescribing practices	34	38	CHALLENGE	cost
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	84	101	CHALLENGE	lack of education
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	106	128	CHALLENGE	training in physicians
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	146	187	CHALLENGE	poor characterization of drug-related PGx
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	189	210	CHALLENGE	unspecific biomarkers
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	214	240	CHALLENGE	drug efficacy and toxicity
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	242	260	CHALLENGE	cost-effectiveness
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	262	309	CHALLENGE	administrative problems in health organizations
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	315	369	CHALLENGE	insufficient regulation for the generalized use of PGx
improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic	63	101	CHALLENGE	efficient multi-gene genotyping panels
improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic	104	157	CHALLENGE	outine pretreatment testing for these gene-drug pairs
The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs	98	154	CHALLENGE	lack of clarity about who will bear the associated costs
Numerous additional pharmacogenomic associations have been reported concerning antimicrobial-related idiosyncratic adverse drug reactions, particularly involving specific HLA alleles, but, to date, the cost-effectiveness of genotyping prior to prescription has not been confirmed	224	256	CHALLENGE	genotyping prior to prescription
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	60	86	CHALLENGE	evaluation of the evidence
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	97	116	CHALLENGE	clinical usefulness
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	118	136	CHALLENGE	cost-effectiveness
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	142	167	CHALLENGE	operational requirements
The description of SNPs in pharmacogenes and the establishment of their relationship with the pharmacokinetics of an individual offer an individualized approach that allows us to reduce the unfavorable outcomes of a therapy, ensure better adherence to treatment, prevent the emergence of MDR strains, reduce the cost of treatment, and improve the quality of patients' lives	45	127	CHALLENGE	the establishment of their relationship with the pharmacokinetics of an individual
However, although such pharmacogenetic variations have been estimated to account for a considerable amount of the heritable variability in drug response and toxicity, accurate interpretation at the level of the individual patient remains challenging	167	190	CHALLENGE	accurate interpretation
While current guidelines concerning clinical implementation mostly act upon well-documented, common single nucleotide variants to guide dosing or drug selection	36	59	CHALLENGE	clinical implementation
challenges related to accurate variant interpretation and biomarker utilization will constitute the dominant barriers to clinical use of NGS in pharmacogenomics in the future.	121	140	CHALLENGE	clinical use of NGS
Ethical concerns, including violation of confidentiality, stigmatization, and social pressure to accept pharmacogenomic testing, are among the many challenges that patients face in the adoption of pharmacogenomic testing	41	56	CHALLENGE	confidentiality
Genotyping cost and frequency of risk alleles in the populations influence the cost-effectiveness outcome	11	15	CHALLENGE	cost
Variants of uncertain significance (VUSs) in these genes are discovered at a rate that outpaces current ability to classify them with databases of previous cases, experimental evaluation, and computational predictors.	134	161	CHALLENGE	databases of previous cases
there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways	147	171	CHALLENGE	defining candidate genes
major challenges of implementation lie at the point of delivery into health-care systems	55	63	CHALLENGE	delivery
economic challenges that face developers of and payers for personalized drugs and companion diagnostics	0	8	CHALLENGE	economic
how can we harness the data to inform clinically actionable measures and how can we use it to develop better predictive risk models	11	68	CHALLENGE	harness the data to inform clinically actionable measures
ethical considerations must inform the construction and deployment of all rare-variation triage strategies, particularly with respect to health disparities arising from unbalanced ancestry representation.	137	155	CHALLENGE	health disparities
The genomic inter-individual heterogeneity remains a significant challenge for both clinical decision-making and the design of clinical trials	29	42	CHALLENGE	heterogeneity
Despite demonstrating great value for the identification of single nucleotide variants (SNVs) and insertion/deletions (INDELs), these assays do not permit identification of large structural variants, nor do they allow unambiguous haplotype phasing for star-allele assignment.	155	198	CHALLENGE	identification of large structural variants
the implementation of pharmacogenomics in routine clinical practice presents significant challenges	4	18	CHALLENGE	implementation
However, the implementation of PGx studies during clinical development presents a number of challenges	13	27	CHALLENGE	implementation
Challenges to integrating genomics-based medicine into health care systems include tumor and biologic heterogeneity	14	25	CHALLENGE	integrating
One of the major barriers to implementing clinical pharmacogenomics has been the efficient integration of rapid turnaround-time genetic testing into routine clinical practice	91	102	CHALLENGE	integration
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce.	178	191	CHALLENGE	knowledge gap
Lack of knowledge of genomics and pharmacogenomics among pharmacists was one of the most prominent findings	0	17	CHALLENGE	Lack of knowledge
effective patient educational materials are limited	44	51	CHALLENGE	limited
Nevertheless, PGx consultation prior to prescribing therapeutics is not yet mainstream.	14	86	CHALLENGE	PGx consultation prior to prescribing therapeutics is not yet mainstream
The impact of recurrent pathogenic variants is often understood, however there is a long tail of rare genetic variants that are uncharacterized.	97	118	CHALLENGE	rare genetic variants
The problem of uncharacterized rare variation is especially acute when it occurs in genes of known clinical importance with functionally consequential variants and associated mechanisms.	31	45	CHALLENGE	rare variation
Challenges related to rare-variant pharmacogenomics	22	34	CHALLENGE	rare-variant
Overcoming the gap between 'big data'-derived model predictions and real-world clinical outcomes arguably constitutes one of the greatest challenges of 21st century medical science	68	78	CHALLENGE	real-world
translation of the obtained genomic information into actionable clinical advice lags behind	0	11	CHALLENGE	translation
We discuss emerging strategies and concepts to close this translational gap.	58	75	CHALLENGE	translational gap
Interindividual variability in drug efficacy and toxicity is a major challenge in clinical practice	16	27	CHALLENGE	variability
A major methodological challenge in pharmacogenomics is ascertaining the causality of identified variants	97	105	CHALLENGE	variants
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	21	36	CHALLENGE	highly-scalable
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	42	57	CHALLENGE	highly-accurate
The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB; www	25	56	DATABASE	Pharmacogenomics Knowledge Base
PharmGKB's website is designed to effectively disseminate knowledge to meet the needs of our users	0	8	DATABASE	PharmGKB
In order to meet the needs of whole genome studies, PharmGKB has added new functionalities, including browsing the variant display by chromosome and cytogenetic locations, allowing the user to view variants not located within a gene	52	60	DATABASE	PharmGKB
PharmGKB has also added functionality to accept, store, display and query high throughput SNP array data	0	8	DATABASE	PharmGKB
The PharmGKB is a publicly available online resource that aims to facilitate understanding how genetic variation contributes to variation in drug response	4	12	DATABASE	PharmGKB
This unit describes how to navigate the PharmGKB Web site to retrieve detailed information on genes and important variants, as well as their relationship to drugs and diseases	40	48	DATABASE	PharmGKB
Workflow on how to use PharmGKB to facilitate design of the pharmacogenomic study is also described in this unit	23	31	DATABASE	PharmGKB
The PharmGKB currently contains information on over 500 drugs, 500 diseases, and 700 genes with genotyped variants	4	12	DATABASE	PharmGKB
The NIH initiated the PharmGKB in April 2000	22	30	DATABASE	PharmGKB
PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways	0	8	DATABASE	PharmGKB
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	88	123	DATABASE	Comparative Toxicogenomics Database
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	131	158	DATABASE	Therapeutic Target Database
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	166	197	DATABASE	Pharmacogenomics Knowledge Base
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	213	221	DATABASE	DrugBank
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	265	270	DATABASE	dbSNP
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	272	278	DATABASE	REBASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	283	295	DATABASE	SNP500Cancer
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	148	156	DATABASE	DrugBank
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	161	169	DATABASE	PharmGKB
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	202	208	DATABASE	STRING
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	229	235	DATABASE	HapMap
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	4	37	DATABASE	Singapore Pharmacogenomics Portal
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	106	114	DATABASE	PharmGKB
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	119	127	DATABASE	DrugBank
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	181	195	DATABASE	HapMap Project
PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about how genetic variations modulate an individual's response to drugs	0	8	DATABASE	PharmGKB
PharmGKB contains information about genetic variations, pharmacokinetic and pharmacodynamic pathways, and the effect of variations on drug-related phenotypes	0	8	DATABASE	PharmGKB
PharmGKB provides very detailed clinical associations between genetic variants and drug response, including genotype-specific drug dosing guidelines, and this procedure will armGKB	0	8	DATABASE	PharmGKB
Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations	77	83	DATABASE	NDF-RT
Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations	143	151	DATABASE	PharmGKB
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	286	311	DATABASE	Protein families database
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	320	359	DATABASE	Kyoto Encyclopedia of Genes and Genomes
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	368	376	DATABASE	Reactome
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	378	385	DATABASE	NetPath
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	418	453	DATABASE	Open Regulatory Annotation Database
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	466	520	DATABASE	Biological General Repository for Interaction Datasets
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	532	563	DATABASE	Pharmacogenomics Knowledge Base
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	576	606	DATABASE	Molecular INTeraction database
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	663	682	DATABASE	CSC Genome Browser
MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese	269	275	DATABASE	HapMap
The PharmGKB website provides a diverse array of PGx information, from annotations of the primary literature to guidelines for adjusting drug treatment based on genetic information	4	12	DATABASE	PharmGKB
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	181	189	DATABASE	PharmGKB
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	175	205	DATABASE	Pharmacogenomics Knowledgebase
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	207	215	DATABASE	PharmGKB
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	221	228	DATABASE	ClinVar
Furthermore, we identified an additional 61 variants with PharmGKB 2A or 2B clinical annotations	58	66	DATABASE	PharmGKB
In this study, we genotyped 80 VIP variants from the PharmGKB in 100 members of Blang volunteers from Yunnan province	53	61	DATABASE	PharmGKB
State-of-the-art knowledge in PGx is mainly available in reference databases such as PharmGKB and reported in scientific biomedical literature	85	93	DATABASE	PharmGKB
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	195	203	DATABASE	PharmGKB
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	135	143	DATABASE	PharmVar
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	213	264	DATABASE	Clinical Pharmacogenetics Implementation Consortium
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	266	270	DATABASE	CPIC
Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB	100	108	DATABASE	PharmGKB
A total of 65 VIP variants located within 33 candidate genes were randomly selected from the PharmGKB database and genotyped using the MassARRAY (iPLEX GOLD) system	93	101	DATABASE	PharmGKB
A total of 65 VIP variants located within 33 candidate genes were randomly selected from the PharmGKB database and genotyped using the MassARRAY (iPLEX GOLD) system	135	144	DATABASE	MassARRAY
Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP)	72	103	DATABASE	Pharmacogenomics Knowledge Base
Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP)	161	185	DATABASE	Variant Effect Predictor
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	193	201	DATABASE	PharmGKB
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	184	188	DATABASE	CMap
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	92	99	DATABASE	ClinVar
Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test	139	170	DATABASE	Pharmacogenomics Knowledge Base
Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB)	185	216	DATABASE	Pharmacogenomics Knowledge Base
Meanwhile, we found several VIP variants that might alter the drug metabolism of cisplatin-cyclophosphamide (CYP2E1), vitamin E (CYP4F2), asthma amlodipine, chlorthalidone, and lisinopril (ACE) through PharmGKB	202	210	DATABASE	PharmGKB
These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)	345	396	DATABASE	Clinical Pharmacogenetics Implementation Consortium
We performed a retrospective analysis of drug plasma concentrations and treatment efficacy in patients bearing at least one relevant PharmGKB variant	133	141	DATABASE	PharmGKB
<b>Materials & methods:</b> We selected 66 VIP variants from PharmGKB (www	61	69	DATABASE	PharmGKB
Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases	97	105	DATABASE	PharmGKB
Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases	110	117	DATABASE	ClinVar
Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence	25	56	DATABASE	pharmacogenomics knowledge base
frameshift, nonsense), and splice site variants with potential deleterious effect and B) clinically validated variants described in the PharmGKB (categories 1, 2 and 3) and/or ClinVar databases	176	183	DATABASE	ClinVar
0% of the individuals carried at least one high risk genotype-predicted phenotype in pharmacogenes with PharmGKB level of evidence 1A for drug interaction	104	112	DATABASE	PharmGKB
0% of the cohort used at least one PharmGKB evidence level 1A drug, and 18	35	43	DATABASE	PharmGKB
To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcase<i>CYP2D6</i>, a gene that metabolizes approximately 25% of all prescribed drugs	159	167	DATABASE	PharmGKB
In this guideline, we will present the genes of interest with level 1 clinical recommendations according to PharmGKB for the two major families of psychotropics: antipsychotics and antidepressants	108	116	DATABASE	PharmGKB
Here, we used Oxford Nanopore Technologies' adaptive sampling to enrich a panel of 1,036 genes with well-documented PGx relevance extracted from the Pharmacogenomics Knowledge Base (PharmGKB)	149	180	DATABASE	Pharmacogenomics Knowledge Base
We utilized PyPGx to identify star alleles (haplotype patterns) and compared allele frequencies across populations using the Pharmacogenomics Knowledgebase PharmGKB	156	164	DATABASE	PharmGKB
54 VIP variants were selected from the Pharmacogenomics Knowledge Base (PharmGKB) and genotyped in 200 Yi individuals	39	70	DATABASE	Pharmacogenomics Knowledge Base
A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided	56	64	DATABASE	PharmVar
A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided	134	185	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Furthermore, we explored the landscape of DPWG pharmacogenes in gnomAD and our in-house cohort as well as compared bioinformatic tools for WGS-based structural variant detection in <i>CYP2D6</i>	64	70	DATABASE	gnomAD
We further assessed the distribution of the identified rare and common pharmacogenomics variants amongst different GnomAD subpopulations	115	121	DATABASE	GnomAD
Overall, our findings show that the use of publicly available sequence data, such as the DiscovEHR dataset and GnomAD, provides an opportunity for a deeper understanding of genetic variation in pharmacogenes with direct implications in clinical pharmacogenomics	89	98	DATABASE	DiscovEHR
3% of variants absent from gnomAD database	27	33	DATABASE	gnomAD
Here, we analyzed sequence variation data in 141,456 individuals from across eight study populations in gnomAD for 38 CYP genes to identify such variants in addition to common variants	104	110	DATABASE	gnomAD
Certain common functional variants including NUDT15 13:48611934 G/A (rs186364861), UGT1A1 2:234676872 C/T (rs34946978), and ALDH2 12:112241766 G/A (rs671) were population-specific for CMDB Chinese because they were absent (with a zero of variant allele frequency) or very rare in other gnomAD populations	286	292	DATABASE	gnomAD
Differences in variant allele frequency were observed among the populations studied and the corresponding gnomAD population for 7	106	112	DATABASE	gnomAD
Allelic frequencies were compared to other populations reported in the public gnomAD database	78	84	DATABASE	gnomAD
We compare our allelic frequencies with these from populations described in the gnomAD database	80	86	DATABASE	gnomAD
We demonstrate ePGA's functionality on genetic variation data from the 1000 Genomes Project	71	91	DATABASE	1000 Genomes Project
The 1000 Genomes Project data were analyzed to describe population genetic variation and statistics for these five genes in self-reported healthy individuals in five global super- and 26 sub-populations	4	24	DATABASE	1000 Genomes Project
Herein, we exploit ePGA, a web-based electronic Pharmacogenomics Assistant and publicly available genetic data from the 1000 Genomes Project to explore genotype to phenotype associations among the 1000 Genomes Project populations	120	140	DATABASE	1000 Genomes Project
This study aims to identify and characterize likely causal variants within well-established pharmacogenomic genes using next-generation sequencing data from the 1000 Genomes Project	161	181	DATABASE	1000 Genomes Project
77 M small indels, identified from 991 Chinese individuals of the Chinese Academy of Sciences Precision Medicine Initiative Project (CASPMI) and 301 Chinese individuals of the 1000 Genomes Project (1KGP)	176	196	DATABASE	1000 Genomes Project
This study aimed to identify the distribution differences of very important pharmacogene (VIP) variants between the Tibetan population and the other 26 populations from the 1000 Genomes project	173	193	DATABASE	1000 Genomes project
To test potential associations between noncoding and coding pharmacogenetic variants, we computed a drug-level GVB for 5099 drugs from DrugBank for 2504 genomes of the 1000 Genomes Project and evaluated the correlation between the long-known noncoding variant-drug associations in PharmGKB, with functionally relevant rare and common coding variants aggregated into GVBs	168	188	DATABASE	1000 Genomes Project
The apparent discrepancy with our previous results for NUDT15 rs116855232 in the Ad Mixed American superpopulation of the 1000 Genomes Project is ascribed to the diversity of the Native populations of the Americas	122	142	DATABASE	1000 Genomes Project
Among the accuracy controls were 32 samples from the 1000 Genomes Project that were selected based on their enrichment of sequence variants included in the pharmacogenetic panel (VarCover	53	73	DATABASE	1000 Genomes Project
Frequency of CYP2C19*2, *3 and *17 alleles were obtained from 1000 Genomes project Phase III in line with Fort Lauderdale principles	62	82	DATABASE	1000 Genomes project
In this study, we analyzed the whole-genome sequencing data from The 1000 Genomes Project (Phase 3) and the pharmacogenetic information from Drug Bank, PharmGKB, PharmaADME, and Biotransformation	69	89	DATABASE	1000 Genomes Project
Whole genome sequencing data from the 1000 Genomes Project and the African Genome Variation Project were mined to assess variation in <i>DPYD</i> in eight sub-Saharan African populations	38	58	DATABASE	1000 Genomes Project
In contrast, long-read HiFi sequencing phased all variants across the NUDT15 amplicons, including a *2/*9 diplotype that previously was characterized as *1/*2 in the 1000 Genomes Project v3 data set	166	186	DATABASE	1000 Genomes Project
This let us to compare the frequency of gene variants involved in response to drugs among our population and others, taking data from the 1000 Genomes Project	138	158	DATABASE	1000 Genomes Project
The genotype distribution data of 26 populations were downloaded from the 1000 Genomes Project and analyzed with the \u03c7<sup>2</sup> test	74	94	DATABASE	1000 Genomes Project
<b>Results:</b> Among the 26 populations in the 1000 Genomes Project, African Caribbeans in Barbados; Esan in Nigeria; Gambian in Western Divisions, The Gambia; Luhya in Webuye, Kenya; Yoruba in Ibadan; Finnish in Finland; Toscani in Italy\u00a0and Sri Lankan Tamil in the UK were the top eight nationalities with the most significant differences in genotype distribution from the Lisu population	48	68	DATABASE	1000 Genomes Project
These assessments encompass reference materials from the Genome-In-A-Bottle (GIAB), the Genetic Testing Reference Material Coordination Program (GeT-RM) projects, as well as additional samples from the 1000 Genomes project (1KGP)	202	222	DATABASE	1000 Genomes project
The allele frequencies and genotype distribution data of 26 populations were obtained from the 1000 Genomes Project, followed by a comparison and statistical analysis	95	115	DATABASE	1000 Genomes Project
We developed a new method to construct haplogroups, representing a common ancestry structure, by iteratively excluding rare and functional variants of the 25 representative pharmacogenes using the 2504 genomes from the 1000 Genomes Project	219	239	DATABASE	1000 Genomes Project
We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data	177	182	DATABASE	dbSNP
We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data	193	199	DATABASE	HapMap
While sequence data about genetic variation is found at databases such as dbSNP, clues about the functional and phenotypic consequences of the variations are generally found in biomedical literature	74	79	DATABASE	dbSNP
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	52	56	DATABASE	LOKI
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	147	152	DATABASE	dbSNP
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	234	238	DATABASE	NCBI
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	281	283	DATABASE	GO
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	313	317	DATABASE	Pfam
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	361	365	DATABASE	KEGG
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	522	529	DATABASE	BioGrid
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	565	573	DATABASE	PharmGKB
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	608	612	DATABASE	MINT
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	662	682	DATABASE	UCSC Genome Browser
While it is arguably the most comprehensive source of genetic information, the NCBI's dbSNP database (National Center for Biotechnology Information database of single nucleotide polymorphisms; http://www	86	91	DATABASE	dbSNP
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	14	20	DATABASE	GenoDB
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	47	56	DATABASE	NCBI Gene
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	58	65	DATABASE	Clinvar
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	67	73	DATABASE	Medgen
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	75	80	DATABASE	dbSNP
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	82	86	DATABASE	KEGG
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	88	96	DATABASE	PharmGKB
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	98	105	DATABASE	Uniprot
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	111	120	DATABASE	Hugo Gene
We compare and report here on the observed SNP genetic variation in our sample with data on 12 world populations from dbSNP and discuss the feasibility of forecasting the pharmacokinetics of drugs utilized by migrant communities in Mersin and the Eastern Mediterranean region	118	123	DATABASE	dbSNP
In total, 18,245 variants were identified of which 2565 were novel variants (without rs number in dbSNP build 150) in the testing phase	98	103	DATABASE	dbSNP
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	210	214	DATABASE	TCGA
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	185	208	DATABASE	The Cancer Genome Atlas
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	117	121	DATABASE	CNAs
When applied to platinum-treated patients gathered from TCGA, the model predicted treatment-specific response	56	60	DATABASE	TCGA
The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network	95	118	DATABASE	The Cancer Genome Atlas
The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network	120	124	DATABASE	TCGA
Here, we have developed a novel computational method that allows us to impute drug response in very large clinical cancer genomics data sets, such as The Cancer Genome Atlas (TCGA)	150	173	DATABASE	The Cancer Genome Atlas
Here, we have developed a novel computational method that allows us to impute drug response in very large clinical cancer genomics data sets, such as The Cancer Genome Atlas (TCGA)	175	179	DATABASE	TCGA
We applied a transcriptome based drug sensitivity prediction method, to the Cancer Genome Atlas (TCGA) ovarian cancer dataset to impute patient tumor response to over 100 different drugs	76	95	DATABASE	Cancer Genome Atlas
We applied a transcriptome based drug sensitivity prediction method, to the Cancer Genome Atlas (TCGA) ovarian cancer dataset to impute patient tumor response to over 100 different drugs	97	101	DATABASE	TCGA
In addition, COAC-inferred subnetworks from melanoma patients' scRNA-seq profiles are highly correlated with survival rate from The Cancer Genome Atlas (TCGA)	128	151	DATABASE	The Cancer Genome Atlas
In addition, COAC-inferred subnetworks from melanoma patients' scRNA-seq profiles are highly correlated with survival rate from The Cancer Genome Atlas (TCGA)	153	157	DATABASE	TCGA
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	165	169	DATABASE	TCGA
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	129	133	DATABASE	CTRP
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	92	127	DATABASE	Cancer Therapeutics Response Portal
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	50	79	DATABASE	Cancer Cell Line Encyclopedia
By comparing with the western gastric cancer patients collected from TCGA data portal, some unique characteristics for patients in QTP are suggested	69	73	DATABASE	TCGA
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	218	222	DATABASE	OMIM
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	225	233	DATABASE	DrugBank
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	239	248	DATABASE	GeneCards
<b>Methods:</b> In the present study, we conducted a multi-omics analysis, including gene expression, methylation status, DNA alterations, pharmacogenomics, and survival status based on data from the Cancer Genome Atlas (TCGA) database to discern expression patterns and prognostic roles of BATF in tumors	221	225	DATABASE	TCGA
<b>Methods:</b> In the present study, we conducted a multi-omics analysis, including gene expression, methylation status, DNA alterations, pharmacogenomics, and survival status based on data from the Cancer Genome Atlas (TCGA) database to discern expression patterns and prognostic roles of BATF in tumors	200	219	DATABASE	Cancer Genome Atlas
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	90	94	DATABASE	TCGA
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	99	102	DATABASE	GEO
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	237	240	DATABASE	PFS
Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with high <i>MKX-AS1</i> expression status had significantly worse overall survival (HR = 3	72	76	DATABASE	TCGA
Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with high <i>MKX-AS1</i> expression status had significantly worse overall survival (HR = 3	51	70	DATABASE	Cancer Genome Atlas
We applied the model to tumors in The Cancer Genome Atlas (TCGA) dataset and examined associations between predicted cell viability and mutation status or gene expression levels to understand underlying mechanisms of potential value for drug repurposing	59	63	DATABASE	TCGA
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	99	122	DATABASE	The Cancer Genome Atlas
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	124	128	DATABASE	TCGA
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	131	157	DATABASE	Genotype-Tissue Expression
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	159	163	DATABASE	GTEx
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	166	189	DATABASE	Gene Expression Omnibus
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	191	194	DATABASE	GEO
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	205	224	DATABASE	Human Protein Atlas
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	226	229	DATABASE	HPA
The research relied on data from the 1000 Genomes Project to assess population-specific genetic variations.	37	57	DATABASE	1000 Genomes Project
The Allele Frequency Aggregator (ALFA) database was utilized to explore allele frequencies of pharmacogenomic interest.	4	31	DATABASE	Allele Frequency Aggregator
The study employed the Allele Frequency Net Database to assess population-level genetic variability in pharmacogenes.	23	52	DATABASE	Allele Frequency Net Database
The BioVU DNA databank was instrumental in identifying pharmacogenomic predictors of adverse drug reactions.	4	13	DATABASE	BioVU DNA
Pharmacogenomic data from the Cancer Genome Atlas (TCGA) were employed to study drug resistance mechanisms.	30	49	DATABASE	Cancer Genome Atlas
Pharmacogenomic data were sourced from public databases such as ClinVar and PharmGKB.	64	71	DATABASE	ClinVar
we provide a review of recent developments in computational pharmacogenomics with respect to CMap and LINCS and related applications.	93	97	DATABASE	CMap
Using the CPIC database, we correlated genetic variants with clinical dosing guidelines.	10	14	DATABASE	CPIC
Clinical trial data were extracted from the dbGaP database for pharmacogenomic analysis.	44	49	DATABASE	dbGaP
We accessed data from the dbGAP to perform a pharmacogenomic study on drug response variability.	26	31	DATABASE	dbGAP
Data from the dbGaP database were analyzed to uncover genetic factors influencing drug efficacy.	14	19	DATABASE	dbGaP
The research utilized the dbSNP database to identify single nucleotide polymorphisms relevant to drug efficacy.	26	31	DATABASE	dbSNP
The NCBI dbSNP database was used to catalog single nucleotide polymorphisms relevant to drug response.	9	14	DATABASE	dbSNP
Data from the DME Pharmacogenomics Database were critical in analyzing drug-metabolizing enzyme variants.	14	34	DATABASE	DME Pharmacogenomics
The use of electronic health records (EHR) databases enabled large-scale pharmacogenomic studies.	11	36	DATABASE	electronic health records
Clinical pharmacogenomic data were retrieved from the Electronic Medical Records and Genomics (eMERGE) Network.	54	93	DATABASE	Electronic Medical Records and Genomics
Using the eMERGE Network database, we linked electronic health record data with pharmacogenomic variants.	10	16	DATABASE	eMERGE
We utilized the Ensembl database to annotate genetic variants involved in drug response.	16	23	DATABASE	Ensembl
Genomic data from the ExAC database were utilized to investigate rare variants affecting drug metabolism.	22	26	DATABASE	ExAC
Genomic variants were extracted from the ExAC database to assess their impact on drug metabolism pathways.	41	45	DATABASE	ExAC
The study employed data from the FDA Adverse Event Reporting System (FAERS) database to link genetic factors with drug safety.	33	67	DATABASE	FDA Adverse Event Reporting System
Pharmacogenomic data from the Gene Expression Omnibus (GEO) database were analyzed to identify expression patterns.	30	53	DATABASE	Gene Expression Omnibus
Data mining techniques were applied to the GWAS Catalog database to identify pharmacogenomic associations.	43	55	DATABASE	GWAS Catalog
The study's findings were validated using data from the HapMap database.	56	62	DATABASE	HapMap
We leveraged data from the International HapMap Project to enhance pharmacogenomic analyses.	41	47	DATABASE	HapMap
Data from the Human Genome Variation Database (HGVD) were integrated into our pharmacogenomic analysis.	47	51	DATABASE	HGVD
The Human Cytochrome P450 Allele Nomenclature Database provided critical data for our analysis of metabolic enzymes.	4	45	DATABASE	Human Cytochrome P450 Allele Nomenclature
Data from the Human Gene Mutation Database (HGMD) were used to investigate pharmacogenomic mutations.	14	42	DATABASE	Human Gene Mutation Database
The International Warfarin Pharmacogenetics Consortium database provided data for our study on anticoagulant therapy.	4	63	DATABASE	International Warfarin Pharmacogenetics Consortium database
Data from the iPGxDB database were pivotal in identifying population-specific pharmacogenomic markers.	14	20	DATABASE	iPGxDB
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	222	273	DATABASE	Clinical Pharmacogenetics Implementation Consortium
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	289	325	DATABASE	Dutch Pharmacogenetics Working Group
Data from the International Serious Adverse Event Consortium (iSAEC) database were analyzed to investigate genetic predispositions.	62	67	DATABASE	iSAEC
Data from the Japanese Pharmacogenomics Data Science Consortium database were used to explore ethnic differences in drug response.	14	63	DATABASE	Japanese Pharmacogenomics Data Science Consortium
Large-scale perturbation databases, such as Connectivity Map (CMap) or Library of Integrated Network-based Cellular Signatures (LINCS)	0	24	DATABASE	Large-scale perturbation
The study leveraged the Mayo Clinic RIGHT Protocol database for pharmacogenomic implementation research.	24	50	DATABASE	Mayo Clinic RIGHT Protocol
relevant treatments are being discovered in precision psychiatry research by employing neuroimaging and multi-omics	104	115	DATABASE	multi-omics
Data from the NHGRI-EBI GWAS Catalog were integrated to identify pharmacogenomic associations with drug response.	14	28	DATABASE	NHGRI-EBI GWAS
We extracted pharmacogenomic data from the NIGMS Pharmacogenetics Research Network database.	43	82	DATABASE	NIGMS Pharmacogenetics Research Network
The study used the Population Architecture using Genomics and Epidemiology (PAGE) database to investigate diverse population groups.	76	80	DATABASE	PAGE
The PGRNseq dataset provided essential pharmacogenomic variant information for our analysis.	4	11	DATABASE	PGRNseq
Data from the Pharmacogenomics Research Network (PGRN) were essential for our study.	14	47	DATABASE	Pharmacogenomics Research Network
Data were retrieved from the PharmGKB database to analyze genetic variants associated with drug metabolism.	29	37	DATABASE	PharmGKB
The pharmacogenomic data were sourced from the PharmGKB database, focusing on gene-drug interaction profiles.	47	55	DATABASE	PharmGKB
The study utilized the PharmGKB database to compile comprehensive drug-gene interaction data.	23	31	DATABASE	PharmGKB
Data from the PharmacoGenomics Knowledge Base (PharmGKB) were used to annotate clinically relevant genetic variants.	47	55	DATABASE	PharmGKB
Data from the PharmVar database were analyzed to study allelic variations in pharmacogenes.	14	22	DATABASE	PharmVar
The Personalized Medicine Research Project (PMRP) database provided crucial data for our pharmacogenomic study.	44	48	DATABASE	PMRP
We utilized the Stanford University Biobank to validate pharmacogenomic findings in a clinical cohort.	16	43	DATABASE	Stanford University Biobank
We utilized the TCGA database to correlate genomic alterations with therapeutic outcomes.	16	20	DATABASE	TCGA
We accessed the TCGA database to examine the association between somatic mutations and chemotherapy response.	16	20	DATABASE	TCGA
The study integrated pharmacogenomic data from the UGT Alleles Nomenclature Database to investigate glucuronidation processes.	51	84	DATABASE	UGT Alleles Nomenclature Database
Genetic data from the UK Biobank were analyzed to explore pharmacogenomic implications in a large cohort.	22	32	DATABASE	UK Biobank
The Utah Population Database provided valuable pharmacogenomic data for our study on familial drug responses.	4	28	DATABASE	Utah Population Database
The current version also supports summary analysis on differentially expressed genes between the HapMap samples of European and African ancestry	97	103	DATABASE	HapMap
The CPNDS database consisted of 93,974 reports of medication use, including 10,475 reports of ADRs, of which 72.6% occurred in pediatric patients (21 years old).	4	18	DATABASE	CPNDS database
The CPNDS database is a valuable resource to identify clinical and genomic predictors of ADRs.	4	18	DATABASE	CPNDS database
CellMinerCDB: NCATS comprises 183 cancer cell lines, with 72 unique to NCATS, including some from previously understudied tissues of origin.	0	12	DATABASE	CellMinerCDB
Clear easy-to-follow instructions are given on how to use big data technologies and public health databases in day-to-day clinical practice.	84	107	DATABASE	public health databases
This study analyzed 942 whole-genome sequences from the Electricity Generating Authority of Thailand (EGAT) cohort to establish a population-specific pharmacogenomic database (TPGxD-1) in the Thai population.	176	183	DATABASE	TPGxD-1
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	78	86	DATABASE	PharmGKB
Publicly available datasets from The Cancer Genome Atlas and Gene Expression Omnibus were analyzed using CIBERSORTx and Weighted Gene Co-expression Network Analysis (WGCNA) to obtain types of highly expressed cell types and gene clusters.	51	84	DATABASE	Atlas and Gene Expression Omnibus
PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about how genetic variations modulate an individual's response to drugs	0	8	DATABASE	PharmGKB
Food and Drug Administration (FDA)	30	33	DATABASE	FDA
Pharmacogenomics Knowledgebase (PharmGKB)	32	40	DATABASE	PharmGKB
The Japonica array provides better imputation performance for Japanese individuals than the existing commercially available SNP arrays with both the 1KJPN panel and the International 1000 genomes project panel	183	211	DATABASE	1000 genomes project project
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	78	100	TECHNIQUE	expression microarrays
In addition to high-density experimental microarrays, low-density, gel-based biochip technology represents a versatile platform for translation of research into clinical practice	67	84	TECHNIQUE	gel-based biochip
DNA-binding motif analysis of the microarray-retrieved deregulated genes in the promoter region revealed NF\u03baB as potential transcription factor involved in cryptotanshinone's mode of action	34	54	TECHNIQUE	Microarray-retrieved
Four selected 3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in <i>GATA4</i>, <i>VKORC1</i>, <i>CALU</i> and <i>GGCX</i> genes, respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method	320	328	TECHNIQUE	PCR-RFLP
All of the 32 samples that were positive by HC2 were also positive by RT-PCR, however 21 samples that were positive by RT-PCR were negative by HC2 test	119	125	TECHNIQUE	RT-PCR
Large-scale whole genome and exome resequencing studies have revealed that humans have a high level of deleterious rare variation, which has important implications for the design of future pharmacogenetics studies	0	24	TECHNIQUE	Large-scale whole genome
Large-scale whole genome and exome resequencing studies have revealed that humans have a high level of deleterious rare variation, which has important implications for the design of future pharmacogenetics studies	29	47	TECHNIQUE	exome resequencing
Genotypic variants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were analyzed by pyrosequencing or by PCR restriction fragment length polymorphism	119	122	TECHNIQUE	PCR
Here we developed a novel, rapid Allele-Specific PCR method for CDA rs2072671 genotyping	49	52	TECHNIQUE	PCR
A total of 332 Romanian individuals were genotyped for the CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms using the PCR-RFLP technique	123	131	TECHNIQUE	PCR-RFLP
Furthermore, genotyping for CYP3A5*3 and CYP3A5*6 was performed by PCR-RFLP	67	75	TECHNIQUE	PCR-RFLP
The SmartAmp method enables us to detect genetic polymorphisms or mutations in target genes within 30-40 min without DNA isolation and PCR amplification	135	138	TECHNIQUE	PCR
Differing from the widely used PCR, the SmartAmp reaction is an isothermal DNA amplification, where the initial step of copying a target sequence from the template DNA is critically important	31	34	TECHNIQUE	PCR
The present study examined two polymorphisms of GRIN1, rs11146020 (G1001C) and rs1126442 (G2108A), in 100 male Thai METH-dependent patients and 103 healthy controls using PCR-RFLP techniques	171	179	TECHNIQUE	PCR-RFLP
Using a PCR array for 84 apoptosis genes, cantharidin treatment upregulated gene expression of caspase-1 and nerve growth factor receptor, but downregulated mRNA expression of Bcl-2 like protein 10, Fas ligand, and tumor necrosis factor-\u03b1	8	11	TECHNIQUE	PCR
RT-PCR analysis also confirmed the down-regulation of SKA2 and BUB1B, and the up-regulation of PPP1R15A, SQSTM1, HSPA1B, and DDIT4 by OGE treatment	0	6	TECHNIQUE	RT-PCR
DNA extraction was performed using phenol chloroform extraction procedure and genotyping by standard Taqman based RT-PCR method	114	120	TECHNIQUE	RT-PCR
Major CYP2D6 alleles of *1, *3, *4, *5, and *6 were genotyped for 30 responsive and 60 non-responsive FMF patients by multiplex PCR-based reverse-hybridization StripAssay and real-time PCR methods	128	131	TECHNIQUE	PCR
Here we developed a modified PR-PCR method using a ddNTP-blocked primer and a mixture of DNA polymerases with and without the 3'-5' proofreading function	29	35	TECHNIQUE	PR-PCR
The modified PR-PCR method is quite capable of detecting various mutation types, including point mutations and insertions/deletions (indels), and allows discrimination amplification when the mismatch is located within the last eight nucleotides from the 3'-end of the ddNTP-blocked primer	13	19	TECHNIQUE	PR-PCR
Current technologies for detecting the variants of these genes are mainly based on real-time PCR	93	96	TECHNIQUE	PCR
521T>C) SNP was performed with allele-specific polymerase chain reaction, whilst polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping the SLCO1B1 rs2306283 (c	149	157	TECHNIQUE	PCR-RFLP
In the second part of the study, consensus real-time polymerase chain reaction (RT-PCR) (Takara Bio Inc	80	86	TECHNIQUE	RT-PCR
All of the 32 samples that were positive by HC2 were also positive by RT-PCR, however 21 samples that were positive by RT-PCR were negative by HC2 test	70	76	TECHNIQUE	RT-PCR
In addition, a significant degree of concordance was detected between HC2 and concensus RT-PCR methods (Cohen's kappa: 0	88	94	TECHNIQUE	RT-PCR
Finally, the newly predicted miRNAs for tamoxifen and metformin were experimentally validated in MCF-7 and MDA-MB-231 breast cancer cell lines via qRT-PCR assays	147	154	TECHNIQUE	qRT-PCR
TPMT activity was measured by using a non-extraction HPLC method and genotype for the C3435T polymorphism of MDR1 gene was determined in 215 unrelated IBD patients including of 85 males and 130 females and 212 unrelated healthy individuals consisted of 96 males and 116 females as control group by PCR-RFLP in Iran's western population	38	57	TECHNIQUE	non-extraction HPLC
The device combines a blood lysis chamber, a cross-flow filter, a T-junction mixer, and a microreactor for quantitative polymerase chain reaction (qPCR)	147	151	TECHNIQUE	qPCR
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	66	82	TECHNIQUE	AmpliChip CYP450
Genotyping was conducted by the QuantStudio 12K Flex Real-Time PCR System using a custom open array chip with metabolism, transport, and transcription factor polymorphisms of interest to cisplatin disposition and toxicity	32	73	TECHNIQUE	QuantStudio 12K Flex Real-Time PCR System
Frequency distribution of SULT1A1 copy number (CN) in 157 healthy Indian individuals was assessed using florescent-based quantitative PCR assay	134	143	TECHNIQUE	PCR assay
Genotyping was performed by TaqMan real-time polymerase chain reaction (PCR) (pharmacokinetics genes: cytochrome P450 2D6 (CYP2D6) *4 (rs3892097), *5 (gene deletion), *10 (rs1065852) and *41 (rs28371725), ATP-binding cassette transporter B1 (ABCB1) 2677\u00a0G>T/A (rs2032582) and 3435C>T (rs1045642) and pharmacodynamics genes: dopamine receptor D2 (DRD2) Tag-SNP (C>T) (rs4436578), DRD2 Tag1A (C>T) (rs1800497), leptin gene (LEP) -2548G>A (rs7799039), ghrelin gene (GHRL) -604G>A (rs27647) and brain-derived neurotrophic factor (BDNF) 196G>A (rs6265))	28	70	TECHNIQUE	TaqMan real-time polymerase chain reaction
PCR and direct sequencing revealed a total of 32 polymorphisms, of which 5 novel mutations were presented	0	3	TECHNIQUE	PCR
PCR and direct sequencing revealed a total of 32 polymorphisms, of which 5 novel mutations were presented	8	25	TECHNIQUE	direct sequencing
DNA was extracted from buccal swabs obtained from 636 non-related Southeastern European Caucasian individuals and was analyzed by real-time PCR	130	143	TECHNIQUE	real-time PCR
Polymorphism genotypes were determined by real-time PCR using validated assays	42	55	TECHNIQUE	real-time PCR
Genotypes were determined by means of Taq Man probes (qPCR)	38	52	TECHNIQUE	Taq Man probes
Genotypes were determined by means of Taq Man probes (qPCR)	54	58	TECHNIQUE	qPCR
Real Time PCR (Melting Curve Analysis) followed DNA extraction from buccal swabs and statistical analysis of the results was performed	0	13	TECHNIQUE	Real Time PCR
Variants in OPRM1 (A118G), ABCB1 (C3435T), COMT (G472A), OPRD1 (T921C) and ARRB2 (C8622T) genes were tested by real-time PCR	111	124	TECHNIQUE	real-time PCR
Allelic discrimination was performed by real-time PCR	40	53	TECHNIQUE	real-time PCR
Four selected 3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in <i>GATA4</i>, <i>VKORC1</i>, <i>CALU</i> and <i>GGCX</i> genes, respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method	261	271	TECHNIQUE	simple PCR
PCR and next generation sequencing were used for the analysis	0	3	TECHNIQUE	PCR
PCR and next generation sequencing were used for the analysis	8	34	TECHNIQUE	next generation sequencing
Significant pairs were prioritized based on strength of association and <i>in-silico</i> miRNA target prediction analyses to select candidates for validation with qRT-PCR	163	170	TECHNIQUE	qRT-PCR
<i>CYP1A2*1F</i> (163C>A; rs762551); <i>CYP2C9*3</i> (1075A>C; rs1057910); and <i>CYP3A5*3</i> (6986A>G; rs776746) polymorphisms were investigated through real-time PCR using TaqMan probes	155	168	TECHNIQUE	real-time PCR
<i>CYP1A2*1F</i> (163C>A; rs762551); <i>CYP2C9*3</i> (1075A>C; rs1057910); and <i>CYP3A5*3</i> (6986A>G; rs776746) polymorphisms were investigated through real-time PCR using TaqMan probes	175	188	TECHNIQUE	TaqMan probes
Eleven variants in the thymidylate synthetase (<i>TYMS</i>), methylenetetrahydrofolate reductase (<i>MTHFR</i>)<i>,</i> dihydrofolate reductase (<i>DHFR</i>), <i>SLC19A1</i> and <i>SLCO1B</i> genes were analyzed in 148 patients, using PCR- and sequencing-based methodology	235	238	TECHNIQUE	PCR
Genomic DNA was extracted from blood samples, and PCR and DNA sequencing were performed to identify genetic variations in the different study groups	50	53	TECHNIQUE	PCR
Genomic DNA was extracted from blood samples, and PCR and DNA sequencing were performed to identify genetic variations in the different study groups	58	72	TECHNIQUE	DNA sequencing
NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively	159	167	TECHNIQUE	PCR-RFLP
NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively	172	189	TECHNIQUE	Sanger sequencing
Genotyping of SOD2 (rs4880), PNPL3 (rs738409) and ABCC1 (rs4148350), CBR1 (rs9024) and ABCG2 (rs2231142) was performed by Tetra-ARMS PCR-based technique to evaluate the genotype-phenotype correlation	122	136	TECHNIQUE	Tetra-ARMS PCR
The patients were genotyped for <i>CYP3A5</i>*3, <i>CYP3A4</i>*1B, <i>CYP3A4</i>*1G, <i>ABCB1</i> G2677T, and <i>ABCB1</i> C3435T polymorphisms by the PCR-RFLP method	151	159	TECHNIQUE	PCR-RFLP
Here, we present two simple novel approaches for the identification of samples carrying either deletions or duplications of the <i>CYP2D6</i> gene; by relative quantification using a singleplex 5'nuclease real-time PCR assay, and by high-resolution melting of PCR products	183	224	TECHNIQUE	singleplex 5'nuclease real-time PCR assay
Drug levels were analyzed using liquid chromatography at different days of therapy, whereas variants in genes encoding transporters and nuclear factors were investigated using real-time PCR	176	189	TECHNIQUE	real-time PCR
Allelic discrimination analysis was performed using a step one real-time PCR machine	63	76	TECHNIQUE	real-time PCR
Here, we present a new method for polymerase chain reaction (PCR) melting curve analysis using one fluorescent probe to discriminate the UGT1A1*1 [(TA)<sub>6</sub> ] and *28 [(TA)<sub>7</sub> ] genotypes	61	64	TECHNIQUE	PCR
Genotypes of 10 SNPs from four different genes were analyzed using the allelic discrimination PCR technique	94	97	TECHNIQUE	PCR
Genotyping was performed using real-time PCR and long-range PCR	31	44	TECHNIQUE	real-time PCR
Genotyping was performed using real-time PCR and long-range PCR	49	63	TECHNIQUE	long-range PCR
Five single-nucleotide polymorphisms were genotyped by real-time PCR assays: prostaglandin-F2\u03b1 receptor (rs3766355, rs3753380); cytochrome-P450 2D6 (rs16947, rs769258); and beta-2-adrenergic receptor (rs1042714)	55	68	TECHNIQUE	real-time PCR
In this study, we evaluated TaqMan PCR for detection of the NUDT15 single-nucleotide polymorphisms (SNPs) and examined the clinical impact of Arg139His on thiopurine-induced leukopenia	28	38	TECHNIQUE	TaqMan PCR
First, we demonstrated that a TaqMan PCR assay successfully detected the Arg139His polymorphism of NUDT15 in clinical samples	30	40	TECHNIQUE	TaqMan PCR
Next, the NUDT15 gene polymorphisms (Arg139Cys and Arg139His) were separately analyzed by TaqMan Real-Time PCR in 189 patients from August 2018 to July 2019	90	110	TECHNIQUE	TaqMan Real-Time PCR
719A>G were detected by PCR-restriction fragment length polymorphism assay and c	24	68	TECHNIQUE	PCR-restriction fragment length polymorphism
The expression of 32 target genes in 80 paired specimens (pre-chemotherapeutic primary tumor, post-chemotherapeutic primary tumor and pulmonary metastasis) obtained from 33 patients diagnosed with OS were analyzed by the real-time PCR methodology	221	234	TECHNIQUE	real-time PCR
Genotyping was performed using PCR-RFLP and direct Sanger sequencing	31	39	TECHNIQUE	PCR-RFLP
Genotyping was performed using PCR-RFLP and direct Sanger sequencing	51	68	TECHNIQUE	Sanger sequencing
However, an imbalance in the PCR amplification of different haplotypes could affect the accuracy of typing results	29	46	TECHNIQUE	PCR amplification
<i>IL5RA</i> mRNA expression level was analyzed in different groups of patients by performing qPCR assays	94	105	TECHNIQUE	qPCR assays
SNPs were analyzed using real-time PCR with TaqMan<sup>\u00ae</sup> probes	25	38	TECHNIQUE	real-time PCR
<i>Results</i>: Based on the analysis of melt profile data for each PCR product, the identification of polymorphisms was carried out	68	71	TECHNIQUE	PCR
In this context, there is reported a case in which a routine PCR-SS approach for genotyping <i>DPYD</i> SNP rs55886062 failed in a proband of African descent	61	67	TECHNIQUE	PCR-SS
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	19	42	TECHNIQUE	whole genome sequencing
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	44	47	TECHNIQUE	WGS
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	123	126	TECHNIQUE	PCR
This preventive measure is essential to avoid sequence frameshifts or primer misalignments arising from SNP occurrences in the genome, which can compromise PCR-SS and lead to genotyping failures	156	162	TECHNIQUE	PCR-SS
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	266	279	TECHNIQUE	Gene Ontology
To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB	116	124	DATABASE	PharmGKB
In this study, we recruited 100 unrelated, healthy Deng people and genotyped them with respect to 76 different single-nucleotide polymorphisms by the PharmGKB database	150	158	DATABASE	PharmGKB
MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese	109	117	DATABASE	PharmGKB
Coding and regulatory regions of 509 genes, selected from PharmGKB and Phenopedia, were sequenced using massive parallel sequencing in blood DNA from 105 breast cancer patients in the testing phase	58	66	DATABASE	PharmGKB
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	81	132	DATABASE	Clinical Pharmacogenetics Implementation Consortium
In the first of a series of PharmGKB tutorials, we introduce the PharmGKB coronavirus disease 2019 (COVID-19) portal and, using examples of drugs found in the portal, demonstrate some of the main features of PharmGKB	65	73	DATABASE	PharmGKB
We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB	171	179	DATABASE	PharmGKB
Filtering the variants according to Pharmacogenomics Knowledge Base (PharmGKB) annotations identified 27 diplotypes and 26 variants with an evident clinical relevance	36	67	DATABASE	Pharmacogenomics Knowledge Base
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	65	73	DATABASE	PharmVar
Evidence from the pharmacogenomic literature is curated into PharmGKB as variant annotations, which can be used to create new clinical annotations or added to existing clinical annotations	61	69	DATABASE	PharmGKB
As more evidence is curated into PharmGKB, the task of maintaining consistency when assessing all the available evidence and assigning an LOE becomes increasingly difficult	33	41	DATABASE	PharmGKB
In combination with increased standardization of how clinical annotations are written, use of this scoring system helps to ensure that PharmGKB clinical annotations continue to be a robust source of pharmacogenomic information	135	143	DATABASE	PharmGKB
"Based on PharmGKB expert guidelines we identified at least one \""actionable\"" variant in all 135 (100%) tested patients"	10	18	DATABASE	PharmGKB
Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test	41	65	DATABASE	Genetic Testing Registry
For another pharmacogenetic hurdle, the speed by which a pharmacogenetic profile for a certain drug can be obtained in an individual patient, there has been a revolution in molecular genetics through the introduction of next generation sequencing (NGS), making it possible to sequence a large number of genes up to the complete genome in a single reaction	220	246	TECHNIQUE	next generation sequencing
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \""post-genomic era\"	41	50	TECHNIQUE	DNA array
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \""post-genomic era\"	68	98	TECHNIQUE	high-throughput DNA sequencing
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \""post-genomic era\"	123	149	TECHNIQUE	Next Generation Sequencing
However, with the rise of new technologies, as next generation sequencing, allowing to obtain pre-emptive genetic information, one must be aware that the question will no longer be whether to genotype or not but rather whether or not to use the information already there	47	73	TECHNIQUE	next generation sequencing
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	196	222	TECHNIQUE	Next Generation Sequencing
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	230	236	TECHNIQUE	RNAseq
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	242	252	TECHNIQUE	microarray
Results from the initial next generation sequencing studies indicate an enrichment of rare variants in pathways and genes that were previously found to be associated with BD	25	51	TECHNIQUE	next generation sequencing
Furthermore, the development of next generation sequencing technology and non-invasive approaches to analyze circulating tumor DNA will make real-time monitoring of the tumor pharmacogenomic markers possible in the clinical routine, rendering precision medicine available to every patient	32	58	TECHNIQUE	next generation sequencing
In the current study, the mRNA and microRNA (miRNA) expression profiles derived from next generation sequencing data for APAP-treated (5 and 10\u00a0mM) HepaRG cells and controls were analyzed systematically	85	111	TECHNIQUE	next generation sequencing
With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples	24	50	TECHNIQUE	next generation sequencing
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	116	142	TECHNIQUE	Next Generation Sequencing
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	211	222	TECHNIQUE	Microarrays
Recent progress in Next Generation Sequencing (NGS) technologies has for the first time allowed to comprehensively map the genetic landscape of human pharmacogenes	19	45	TECHNIQUE	Next Generation Sequencing
Extraordinary advances in high throughput next generation sequencing (NGS) technology and bioinformatics are the main thrust that transforms the current state of healthcare into the era of precision medicine where clinical practice takes individual variability into account	42	68	TECHNIQUE	next generation sequencing
"The manuscripts in following categories are welcome, but not limited to: Application of next generation sequencing in clinical diagnosis, including but not limited to rare genetic disease, complex inherited disease, prenatal/perinatal screening, oncology, organ transplantation and pathogen identification; Novel bioinformatics approaches in human genomics; Single cell sequencing, liquid biopsy and other emerging genomic assays in molecular genetics, pharmacogenomics, oncology and immuno-oncology; Integration of genomics with other \""omics\"" technology in genetic medicine"	89	115	TECHNIQUE	next generation sequencing
High-throughput next generation sequencing (NGS) is a shotgun approach applied in a parallel fashion by which the genome is fragmented and sequenced through small pieces and then analyzed either by aligning to a known reference genome or by de novo assembly without reference genome	16	42	TECHNIQUE	next generation sequencing
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	0	26	TECHNIQUE	Next generation sequencing
It also plays a fundamental role in nucleic acid sequencing applications, including Next Generation Sequencing (NGS)-based ones	84	110	TECHNIQUE	Next Generation Sequencing
PCR and next generation sequencing were used for the analysis	0	3	TECHNIQUE	PCR
PCR and next generation sequencing were used for the analysis	8	34	TECHNIQUE	next generation sequencing
In this study we used next generation sequencing to measure genome-wide miRNA expression in lymphoblastoid cell lines from BD patients excellent responders (ER, <i>n</i> = 12) and non-responders (NR, <i>n</i> = 12) to lithium	22	48	TECHNIQUE	next generation sequencing
In this study we used next generation sequencing to measure genome-wide miRNA expression in lymphoblastoid cell lines from BD patients excellent responders (ER, <i>n</i> = 12) and non-responders (NR, <i>n</i> = 12) to lithium	60	88	TECHNIQUE	genome-wide miRNA expression
For the advances of pediatric oncology next generation sequencing (NGS) research to equitably benefit all children, a diverse and representative sample of participants is needed	39	65	TECHNIQUE	next generation sequencing
The rapid clinical implementation of next generation sequencing techniques\u00a0is\u00a0 due to its ability to sequence a large number of genetic regions at\u00a0lower costs\u00a0 than conventional techniques	37	63	TECHNIQUE	next generation sequencing
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	40	43	TECHNIQUE	PCR
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	45	54	TECHNIQUE	MassArray
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	60	95	TECHNIQUE	targeted next generation sequencing
Here, we report on the development of a cost-effective next generation sequencing-based pain-genotyping assay comprising the development of a customized AmpliSeq\u2122 panel and bioinformatics approaches that condensate the genetic information of pain by identifying the most representative genes	55	87	TECHNIQUE	next generation sequencing-based
<b>Conclusion:</b> The implementation of Precision Medicine by using tools such as Next Generation Sequencing and TDM led to diagnose and select a targeted therapy for the treatment of a KCNT1-related epilepsy in a patient presented with EIMFS in early infancy and poor response to antiepileptic drugs	83	109	TECHNIQUE	Next Generation Sequencing
The increasing availability of next generation sequencing (NGS) for personal genomics could promote pharmacogenomics (PGx) discovery and application	31	57	TECHNIQUE	next generation sequencing
Nowadays, a plethora of studies implement next generation sequencing to capture rare and novel pharmacogenomic (PGx) variants that influence drug response	42	68	TECHNIQUE	next generation sequencing
To assess whether the specific population history of Roma, characterized by constant migrations and endogamy, influenced the distribution of alleles and thus phenotypes, the CYP2D6 gene was sequenced using NGS (Next Generation Sequencing) method-targeted sequencing in three groups of Croatian Roma (N = 323) and results were compared to European and Asian populations	206	209	TECHNIQUE	NGS
To assess whether the specific population history of Roma, characterized by constant migrations and endogamy, influenced the distribution of alleles and thus phenotypes, the CYP2D6 gene was sequenced using NGS (Next Generation Sequencing) method-targeted sequencing in three groups of Croatian Roma (N = 323) and results were compared to European and Asian populations	211	237	TECHNIQUE	next generation sequencing
An innovative multimodal targeted next generation sequencing (mmNGS) approach with custom primers designed for the most commonly reported SNPs of genes belonging to DNA repair, CDDP transport or detoxification, or associated with CDPP-related toxicity was applied	25	60	TECHNIQUE	targeted next generation sequencing
Massively parallel, next generation sequencing (NGS), has allowed pharmacogenetics to be subsumed by pharmacogenomics with respect to the identification of variants associated with responders and non-responders, optimal drug response, and adverse drug reactions	20	46	TECHNIQUE	next generation sequencing
In the near future, we envision a shift toward long-read sequencing as the predominant method for gene diagnostics and pharmacogenetic profiling, providing unprecedented data quality and improving patient care	47	67	TECHNIQUE	long-read sequencing
Here, we show the utility of long-read sequencing to resolve complex pharmacogenes by analyzing a well-characterised sample	29	49	TECHNIQUE	long-read sequencing
Together, these findings suggest that long-read sequencing data offers promising opportunities in elucidating complex pharmacogenes and haplotype phasing while maintaining accurate variant calling	38	58	TECHNIQUE	long-read sequencing
Long-read sequencing, on the other hand, has been shown to be able to resolve complex (pharmaco) genes	0	20	TECHNIQUE	Long-read sequencing
In this study we aimed to assess the value of long-read sequencing for research and clinical PGx focusing on the important and highly polymorphic <i>CYP2C19</i> gene	46	66	TECHNIQUE	long-read sequencing
<b>Methods and Results:</b> With a capture-based long-read sequencing panel we were able to characterize the entire region and assign variants to their allele of origin (phasing), resulting in the identification of 813 unique variants in 37 samples	49	69	TECHNIQUE	long-read sequencing
To improve <i>CYP2D6</i> genotyping accuracy, we developed a PCR-free CRISPR-Cas9 based enrichment method for targeted long-read sequencing that fully characterizes the entire <i>CYP2D6-CYP2D7-CYP2D8</i> loci	61	81	TECHNIQUE	PCR-free CRISPR-Cas9
To improve <i>CYP2D6</i> genotyping accuracy, we developed a PCR-free CRISPR-Cas9 based enrichment method for targeted long-read sequencing that fully characterizes the entire <i>CYP2D6-CYP2D7-CYP2D8</i> loci	110	139	TECHNIQUE	targeted long-read sequencing
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	139	159	TECHNIQUE	long-read sequencing
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	161	181	TECHNIQUE	single-cell genomics
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	187	206	TECHNIQUE	nanopore sequencing
In this study, we employed long-read sequencing technology, extensively utilized in studying complex genomic regions, to characterize genetic alterations, including short variants (single nucleotide variants and short insertions and deletions) and copy number variations, in 370 CMRGs across 41 individuals from 19 global populations	27	47	TECHNIQUE	long-read sequencing
Our results demonstrate that nanopore sequencing is an emerging standalone technology with potential utility in a clinical environment to aid in medical decision-making	29	48	TECHNIQUE	nanopore sequencing
We have established methods for sequencing and haplotyping of the whole <i>CYP2D6</i> gene using nanopore sequencing	97	116	TECHNIQUE	nanopore sequencing
The MinION nanopore sequencing device opens the opportunity to cost-effective and point-of-care DNA sequencing	4	30	TECHNIQUE	MinION nanopore sequencing
We carried out long PCR to isolate the <i>CYP2D6</i> region before performing nanopore sequencing to identify all variants and alleles in these samples	15	23	TECHNIQUE	long PCR
We carried out long PCR to isolate the <i>CYP2D6</i> region before performing nanopore sequencing to identify all variants and alleles in these samples	78	97	TECHNIQUE	nanopore sequencing
Nanopore sequencing has been examined as a method for rapid and high-resolution human leukocyte antigen (HLA) typing in recent years	0	19	TECHNIQUE	Nanopore sequencing
This work advances the use of nanopore sequencing in clinical PGx settings	30	49	TECHNIQUE	nanopore sequencing
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	139	159	TECHNIQUE	long-read sequencing
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	161	181	TECHNIQUE	single-cell genomics
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	187	206	TECHNIQUE	nanopore sequencing
<b>Objectives:</b> We sought to develop a Nanopore sequencing panel and validate its performance in patients with active tuberculosis (TB) to personalize treatment dosing	42	61	TECHNIQUE	Nanopore sequencing
<b>Methods:</b> We developed a Nanopore sequencing panel targeting 15 SNPs in five genes affecting the metabolism of antitubercular drugs	31	50	TECHNIQUE	Nanopore sequencing
In the past decade, pharmacogenomics and microarrays are considered two of the most important scientific breakthroughs for detection and treatment of diseases with many other applications	41	52	TECHNIQUE	microarrays
The IC50 values for miltirone of 60 National Cancer Institute cell lines were associated with the microarray-based expression of 9,706 genes	98	114	TECHNIQUE	Microarray-based
The results obtained from microarray were further validated by real-time reverse transcription-PCR	26	36	TECHNIQUE	microarray
The pharmacogenomic effects of a corticosteroid (CS) were assessed in rat skeletal muscle using microarrays	96	107	TECHNIQUE	microarrays
These technologies include target therapies, toxicogenomics, nanomedicine, pharmacogenetics and pharmacogenomics, with a particular focus on microarray technology	141	151	TECHNIQUE	microarray
Improvements in the sensitivity and precision of DNA microarrays permit a detailed and accurate scrutiny of the human genome	49	64	TECHNIQUE	DNA microarrays
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	38	52	TECHNIQUE	DNA-microarray
However, the comprehensive study of pharmacoepigenomics awaits the advent of genome-wide analysis of DNA methylation using microarrays and next-generation sequencers	101	134	TECHNIQUE	DNA methylation using microarrays
However, the comprehensive study of pharmacoepigenomics awaits the advent of genome-wide analysis of DNA methylation using microarrays and next-generation sequencers	139	166	TECHNIQUE	next-generation sequencers
Novel multistranded and alternative DNA, RNA and plasmid microarrays (transitional structural nucleic acid microarrays) have been developed that allows for the immobilization of intact, nondenatured, double-stranded DNA, double-stranded RNA, and alternative and multistranded nucleic acids	41	68	TECHNIQUE	RNA and plasmid microarrays
This technology represents the next generation of microarrays, which will aid in the characterization of nucleic acid structure and function, and accelerate the discovery of drugs that bind to nucleic acids	50	61	TECHNIQUE	microarrays
These novel nucleic acid microarrays, together with pharmacogenomics, can be used to improve the study of DNA and RNA structure, gene expression, drug development and treatment of various diseases	12	36	TECHNIQUE	nucleic acid microarrays
It is suggested that a systems biology approach employing microarray analyses of gene expression and methylation patterns can lead to a better understanding of long-term side-effects of drugs, and that in the future, epigenetic assays should be incorporated into the safety assessment of all pharmaceutical drugs	58	68	TECHNIQUE	microarray
In addition to high-density experimental microarrays, low-density, gel-based biochip technology represents a versatile platform for translation of research into clinical practice	41	52	TECHNIQUE	microarrays
Gel-based microarrays (biochips) consist of nanoliter gel drops on a hydrophobic surface with different immobilized biopolymers (primarily nucleic acids and proteins)	0	21	TECHNIQUE	Gel-based microarrays
In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling	42	63	TECHNIQUE	microarray-based mRNA
Research into gene diversity through single-nucleotide polymorphisms (SNPs) by means of microarray systems, allows the detailed analysis of gene factors associated to a given disease	88	98	TECHNIQUE	microarray
Screening of microarray data revealed paraoxonases PON1 and PON3 among 17 candidate esterases	13	23	TECHNIQUE	microarray
Potential explanations for low replication rate include differences in microarray platforms, statistical modeling, covariates considered and origin and collection procedures of tissues	71	81	TECHNIQUE	microarray
The advent of microarrays over the past decade has transformed the way genome-wide studies are designed and conducted, leading to an unprecedented speed of acquisition and amount of new knowledge	14	25	TECHNIQUE	microarrays
Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters	0	10	TECHNIQUE	Microarray
Herein, we present a summary of the main applications of whole-genome expression microarrays in the field of molecular-targeted therapies for solid tumors and we discuss their potential in the clinical setting	81	92	TECHNIQUE	microarrays
Increasing numbers of clinically useful DNA microarrays are in the development stage, including a simplified procedure for genotyping patients for CYP2D6, which metabolizes a high proportion of the currently prescribed antidepressants and antipsychotics	40	55	TECHNIQUE	DNA microarrays
We investigated the association of genetic polymorphisms in drug metabolizing enzymes (DMEs) and transporters in patients with docetaxel-induced febrile neutropenia, by a new high-throughput DMEs and transporters (DMETPlus) microarray platform, characterizing 1936 single nucleotide polymorphisms (SNPs) in 225 genes	200	234	TECHNIQUE	transporters (DMETPlus) microarray
We investigated the association of genetic polymorphisms in drug metabolizing enzymes (DMEs) and transporters in patients with docetaxel-induced febrile neutropenia, by a new high-throughput DMEs and transporters (DMETPlus) microarray platform, characterizing 1936 single nucleotide polymorphisms (SNPs) in 225 genes	175	190	TECHNIQUE	high-throughput
Microarray-based mRNA expression profiling, COMPARE, and hierarchical cluster analyses were applied to identify which genes correlate with sensitivity or resistance to selected phytochemicals of the Korean plants	0	42	TECHNIQUE	Microarray-based mRNA expression profiling
Selected phytochemicals from Korean plants were analyzed in more detail using microarray-based mRNA expression profiles and molecular docking to VEGFR1 and VEGFR2	78	119	TECHNIQUE	microarray-based mRNA expression profiles
By using COMPARE analysis of microarray-based transcriptome-wide mRNA expressions, 21 genes were found to significantly correlate with response of 60 tumor cell lines to cantharidin	29	81	TECHNIQUE	microarray-based transcriptome-wide mRNA expressions
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel	79	130	TECHNIQUE	transcriptome-wide microarray-based mRNA expression
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	65	77	TECHNIQUE	PCR (RT-PCR)
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	33	64	TECHNIQUE	real-time reverse transcriptase
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	79	90	TECHNIQUE	microarrays
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	92	118	TECHNIQUE	next-generation sequencing
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	124	146	TECHNIQUE	whole-exome sequencing
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	52	56	TECHNIQUE	eQTL
cDNA microarray assay demonstrated that the expression of cell cycle regulators, apoptosis-related factors and cell proliferation markers were all modified by OGE treatment	0	21	TECHNIQUE	cDNA microarray assay
The surface of the microarray is functionalized with self-assembled monolayers of mercaptoundodecanoic acid or thiolated DNA	19	29	TECHNIQUE	microarray
To develop a gold nanoparticle-based visual DNA microarray for simple and rapid screening of EGFR gene mutations	44	58	TECHNIQUE	DNA microarray
The progress of molecular biology tools (microarrays, proteomics and nanotechnology) have revolutionised the field of the biomarker discovery	41	52	TECHNIQUE	microarrays
Understanding the process microarray testing provides a framework for understanding pharmacogenetic testing	26	36	TECHNIQUE	microarray
The progress of molecular biology tools (microarrays, proteomics, and epigenetics) have progressed the field of the genetic markers discovery	41	52	TECHNIQUE	microarrays
Transcriptomic data were obtained from these samples using Illumina HumanHT-12 v4 Expression BeadChip microarrays	82	113	TECHNIQUE	Expression BeadChip microarrays
Validation of expression of selected candidate genes was determined by evaluating an independent microarray expression data set	97	118	TECHNIQUE	microarray expression
This study presents two rapid and affordable microarray-based strategies to discriminate three clinically important SNPs in genes ADRA2A, SL6CA2, and OPRM1 (rs1800544, rs5569, and rs1799971, respectively)	45	61	TECHNIQUE	microarray-based
Previous studies have relied primarily on microarrays to understand gene expression differences, or have focused on a single tissue or small number of samples	42	53	TECHNIQUE	microarrays
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	230	236	TECHNIQUE	RNAseq
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	242	252	TECHNIQUE	microarray
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	196	222	TECHNIQUE	Next Generation Sequencing
Genotyping was performed using the DMET Plus microarray platform	35	55	TECHNIQUE	DMET Plus microarray
Beg P132 Association of HCV nucleotide polymorphism in the development of hepatocellular carcinoma Mohd Suhail, Abid Qureshi, Adil Jamal, Peter Natesan Pushparaj, Mohammad Al-Qahtani, Ishtiaq Qadri P133 Gene expression profiling by DNA microarrays in colon cancer treated with chelidonine alkaloid Mahmoud Z El-Readi, Safaa Y Eid, Michael Wink P134 Successful <i>in vitro</i> fertilization after eight failed trials Ahmed M	232	247	TECHNIQUE	DNA microarrays
Recent growth in the area of toxicogenomics and pharmacogenomics has provided with a vast amount of drug expression microarray data	116	126	TECHNIQUE	microarray
Therefore, the miRNA-mRNA interactions and drug toxicity were investigated in silico using available microarray data	101	111	TECHNIQUE	microarray
As recognised by the National Institutes of Health (NIH) Precision Medicine Initiative (PMI), microarray technology currently provides a rapid, inexpensive means of identifying large numbers of known genomic variants or gene transcripts in experimental and clinical settings	94	104	TECHNIQUE	microarray
Microarrays presently remain the technology of choice in applications that require fast, cost-effective genome-wide screening of variants of known importance, particularly for large sample sizes	0	11	TECHNIQUE	Microarrays
Recently, the Affymetrix DMET (Drug Metabolizing Enzymes and Transporters) microarray platform has offered the possibility to determine the ADME (absorption, distribution, metabolism, and excretion) gene variants of a patient and to correlate them with drug-dependent adverse events	75	85	TECHNIQUE	microarray
Gene expression profiles predicting sensitivity and resistance of tumor cells to induction by curcumin and AA were determined by microarray-based mRNA expressions, COMPARE, and hierarchical cluster analyses	129	150	TECHNIQUE	microarray-based mRNA
SULT1A1 mRNA and protein levels were quantified using microarray data and Western blot analysis, respectively	54	64	TECHNIQUE	microarray
COMPARE analyses of the NCI microarray database for 60 cell lines showed that several genes, including those involved in lipid metabolism, correlated with cellular responsiveness to niclosamide	28	38	TECHNIQUE	microarray
Forty genes determining cellular responsiveness to As<sub>2</sub>O<sub>3</sub> were identified by microarray and COMPARE analyses in 58 cell lines of the NCI panel	98	108	TECHNIQUE	microarray
This paper presents the design and the experimentation of a comprehensive software pipeline, named microPipe, for the preprocessing, annotation and analysis of microarray-based Single Nucleotide Polymorphism (SNP) genotyping data	160	176	TECHNIQUE	microarray-based
Microarrays and mass spectrometry-based proteomics were employed to quantify hepatic transcript and protein dynamics	0	11	TECHNIQUE	Microarrays
Microarrays and mass spectrometry-based proteomics were employed to quantify hepatic transcript and protein dynamics	16	39	TECHNIQUE	mass spectrometry-based
The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction	146	156	TECHNIQUE	microarray
The optical sensing method in a DNA microarray format was optimized and evaluated for the simultaneous identification of 28 polymorphisms associated with psychiatric pharmacogenomics	32	46	TECHNIQUE	DNA microarray
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	80	90	TECHNIQUE	Microarray
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	95	102	TECHNIQUE	RNA-Seq
Correlation to transcript microarray expression levels for identical genes and identical cell lines across CellMinerCDB demonstrates the high quality of these new RNA-seq data	15	47	TECHNIQUE	transcript microarray expression
Correlation to transcript microarray expression levels for identical genes and identical cell lines across CellMinerCDB demonstrates the high quality of these new RNA-seq data	163	175	TECHNIQUE	RNA-seq data
33 region was interrogated across deidentified clinical chromosomal microarray (CMA) data from 20,642 patients tested at two academic medical centers	68	78	TECHNIQUE	microarray
Fourteen patients with chronic ITP were studied by means of microarrays before and during eltrombopag treatment	60	71	TECHNIQUE	microarrays
The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling	284	287	TECHNIQUE	NGS
The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling	292	303	TECHNIQUE	microarrays
To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts	242	258	TECHNIQUE	microarray-based
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	120	130	TECHNIQUE	microarray
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	132	144	TECHNIQUE	TaqMan assay
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	157	180	TECHNIQUE	mass spectrometry-based
In this work, we studied the effect of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in HCC by constructing tissue microarrays (TAMs) from 90 HCC cases and corresponding para-cancerous tissues	131	142	TECHNIQUE	microarrays
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	59	69	TECHNIQUE	microarray
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	71	96	TECHNIQUE	polymerase chain reaction
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	101	122	TECHNIQUE	short-read sequencing
PK and PGx were evaluated using tandem mass spectrometry and PharmacoScan\u2122 microarray (including <i>CYP3A5*3</i> , <i>*6</i> , and <i>*7</i> )	32	56	TECHNIQUE	tandem mass spectrometry
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	92	115	TECHNIQUE	copy number alterations
The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network	14	38	TECHNIQUE	mRNA expression profiles
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	277	303	TECHNIQUE	single-cell RNA-sequencing
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	305	314	TECHNIQUE	scRNA-seq
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	317	340	TECHNIQUE	spatial transcriptomics
Applying genome editing techniques like TALENs, we generated precise modifications in the model organism's genome.	9	34	TECHNIQUE	genome editing techniques
Applying single-cell DNA sequencing, we uncovered genomic heterogeneity within tumor samples, offering insights into cancer evolution.	9	35	TECHNIQUE	single-cell DNA sequencing
Applying synthetic lethality screens, we identified gene interactions that are critical for cancer cell viability, opening new avenues for targeted therapy.	9	36	TECHNIQUE	synthetic lethality screens
ChIP-seq was utilized to identify the binding sites of transcription factors across the genome, revealing key regulatory elements involved in gene expression.	0	8	TECHNIQUE	ChIP-seq
Compared with current genomic testing strategies, largely focused on small number of genes tested individually or targeted panels, whole-genome and transcriptome sequencing (WGTS) provides novel opportunities to identify and report a potentially much larger number of actionable alterations with diagnostic, prognostic, and/or predictive impact.	148	172	TECHNIQUE	transcriptome sequencing
Compared with current genomic testing strategies, largely focused on small number of genes tested individually or targeted panels, whole-genome and transcriptome sequencing (WGTS) provides novel opportunities to identify and report a potentially much larger number of actionable alterations with diagnostic, prognostic, and/or predictive impact.	174	178	TECHNIQUE	WGTS
DNA methylation profile and differential expression of circulating non-coding RNAs (miRNAs and lncRNAs) will be analyzed in FH patients and normolipidemic subjects (control group)	0	15	TECHNIQUE	DNA methylation
First, mESCs were differentiated into epiblast stem cells (EpiSCs) to enhance the PP differentiation rate	59	65	TECHNIQUE	EpiSCs
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	200	225	TECHNIQUE	Genomas PhyzioType system
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	131	158	TECHNIQUE	LGC clozapine response test
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	88	125	TECHNIQUE	Luminex Tag-It Mutation Detection Kit
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	176	190	TECHNIQUE	Clozapine test
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	55	70	TECHNIQUE	Roche AmpliChip
For further mechanistic validation, Molecular Dynamics simulations were performed, which revealed that certain mismatches showed elevated root mean square deviation (RMSD) values that can be attributed to conformational instability within the RNA-DNA duplex	36	66	TECHNIQUE	Molecular Dynamics simulations
High-throughput molecular profiling of tumors is a fundamental aspect of precision oncology, enabling the identification of genomic alterations	16	35	TECHNIQUE	molecular profiling
In the Neocent study, paired tumour whole exome sequence data was available before and after 21 weeks neoadjuvant therapy and bioinformatics approaches were used to compare exome profiles. Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from in these patients. A related study in patients with metastatic breast cancer (MBC) evaluated NGS analysis of specific mutations using the Oncomine breast cancer cfDNA assay and results were compared with detection of SCNA by sWGS	222	226	TECHNIQUE	sWGS
In the Neocent study, paired tumour whole exome sequence data was available before and after 21 weeks neoadjuvant therapy and bioinformatics approaches were used to compare exome profiles. Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from in these patients. A related study in patients with metastatic breast cancer (MBC) evaluated NGS analysis of specific mutations using the Oncomine breast cancer cfDNA assay and results were compared with detection of SCNA by sWGS	531	535	TECHNIQUE	sWGS
In the Neocent study, paired tumour whole exome sequence data was available before and after 21 weeks neoadjuvant therapy and bioinformatics approaches were used to compare exome profiles. Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from in these patients. A related study in patients with metastatic breast cancer (MBC) evaluated NGS analysis of specific mutations using the Oncomine breast cancer cfDNA assay and results were compared with detection of SCNA by sWGS	197	220	TECHNIQUE	whole genome sequencing
In this paper, we establish a multi-stage fiber amplifier with pseudo-random binary sequence (PRBS) phase modulation	94	98	TECHNIQUE	PRBS
Microarray analysis was performed to assess the gene expression changes in response to environmental stress, offering a high-throughput approach to study transcriptional regulation.	0	19	TECHNIQUE	Microarray analysis
Microarray analysis was performed using plasma from six patients without anemia and six patients with anemia, and nine miRNAs were differentially expressed.	0	10	TECHNIQUE	Microarray
miR-1273g-3p, miR-3613-5p and miR-455-3p, identified using microarray, were assessed using qPCR in 20 patients without anemia and 26 patients with anemia.	91	95	TECHNIQUE	qPCR
Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection.	0	19	TECHNIQUE	Molecular profiling
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries.	0	26	TECHNIQUE	Next-generation sequencing
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries.	28	31	TECHNIQUE	NGS
Next-generation sequencing (NGS) is used increasingly in hereditary cancer patients' (HCP) management	0	26	TECHNIQUE	Next-generation sequencing
Next-generation sequencing (NGS) is used increasingly in hereditary cancer patients' (HCP) management	28	31	TECHNIQUE	NGS
Next-generation sequencing (NGS) represents a rapid, relatively inexpensive, large-scale DNA sequencing technology with potential relevance as a comprehensive pharmacogenetic genotyping platform to identify genetic variation related to drug therapy.	0	26	TECHNIQUE	Next-generation sequencing
Our research applied whole-genome sequencing to identify novel genetic variants linked to Alzheimer's disease, highlighting the potential of comprehensive genomic approaches.	21	44	TECHNIQUE	whole-genome sequencing
Sequencing of circulating tumor DNA (ctDNA) in blood samples provided a non-invasive method for monitoring cancer progression.	14	35	TECHNIQUE	circulating tumor DNA
Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from these patients.	33	37	TECHNIQUE	sWGS
Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from these patients.	8	31	TECHNIQUE	whole genome sequencing
Since the days of Sanger sequencing, next-generation sequencing technologies have significantly evolved to provide increased data output, efficiencies, and applications	37	76	TECHNIQUE	next-generation sequencing technologies
Since the days of Sanger sequencing, next-generation sequencing technologies have significantly evolved to provide increased data output, efficiencies, and applications	18	35	TECHNIQUE	Sanger sequencing
Single-cell multi-omics approaches combined RNA sequencing and epigenetic profiling to provide a comprehensive view of cellular states.	0	23	TECHNIQUE	Single-cell multi-omics
Single-cell RNA sequencing analysis revealed a larger endocrine population within the PP + MP aggregates, as compared to PPs alone or PPs in Matrigel aggregates	0	26	TECHNIQUE	Single-cell RNA sequencing
The application of single-cell ATAC-seq allowed for the profiling of chromatin accessibility at a single-cell level, providing insights into gene regulatory networks.	19	39	TECHNIQUE	single-cell ATAC-seq
"The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a ""genomic era""of cancer research and treatment."	20	46	TECHNIQUE	Next-generation-sequencing
The last decade has seen rapid progress in the use of genomic tests, including gene panels, whole-exome sequencing , and whole-genome sequencing, in research and clinical cancer	92	114	TECHNIQUE	whole-exome sequencing
The NeuroIDgenetix test uses a genetic variant panel of ten genes, along with concomitant medications, to make medication management recommendations based on gene-drug and drug-drug interactions for over 40 medications used in the treatment of depression and anxiety	4	18	TECHNIQUE	NeuroIDgenetix
The stimulated Brillouin gain spectra of the main amplifier with both the unmodulated and pseudo-random binary sequence phase modulated configuration are measured (with corresponding output power)	90	119	TECHNIQUE	pseudo-random binary sequence
The stimulated Brillouin gain spectra of the main amplifier with both the unmodulated and pseudo-random binary sequence phase modulated configuration are measured (with corresponding output power)	4	37	TECHNIQUE	stimulated Brillouin gain spectra
The stimulated Brillouin scattering reflectivity is below 0.01% at 3.05 kW at 13.7 GHz, which indicates that stimulated Brillouin scattering can be suppressed efficiently at this power and linewidth level	4	48	TECHNIQUE	stimulated Brillouin scattering reflectivity
The study employed amplicon sequencing to analyze the diversity of microbial communities in environmental samples.	19	38	TECHNIQUE	amplicon sequencing
The therapeutic application of CRISPR-Cas9 is limited due to its off-target activity	31	42	TECHNIQUE	CRISPR-Cas9
The utilization of CRISPR activation (CRISPRa) enabled the upregulation of target gene expression, facilitating functional genomic studies.	19	25	TECHNIQUE	CRISPR
The utilization of CRISPR activation (CRISPRa) enabled the upregulation of target gene expression, facilitating functional genomic studies.	38	45	TECHNIQUE	CRISPRa
This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels.	52	78	TECHNIQUE	next-generation sequencing
This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels.	80	83	TECHNIQUE	NGS
This review provides an overview of these technologies as two paradigms: short-read, or second-generation, technologies, and long-read, or third-generation, technologies	73	83	TECHNIQUE	short-read
This study employs CRISPR-Cas9 to investigate the functional roles of candidate genes in cancer cells, demonstrating the utility of gene editing technologies.	19	30	TECHNIQUE	CRISPR-Cas9
This study provides clinicians and researchers with an informed choice between current commercially available targeted sequencing panels and exome sequencing panels in the context of pan-cancer pharmacogenetics.	141	157	TECHNIQUE	exome sequencing
Through exome sequencing, we focused on the protein-coding regions of the genome to identify deleterious mutations associated with rare genetic disorders.	8	24	TECHNIQUE	exome sequencing
Using clustered regularly interspaced short palindromic repeats interference (CRISPRi), we achieved targeted gene repression in mammalian cells.	78	85	TECHNIQUE	CRISPRi
Using high-throughput CRISPR screens, we identified essential genes for cancer cell survival, highlighting potential therapeutic targets.	22	28	TECHNIQUE	CRISPR
Using methylation sequencing, we mapped the DNA methylation landscape in cancer tissues, uncovering epigenetic modifications linked to tumorigenesis.	6	28	TECHNIQUE	methylation sequencing
Utilizing digital droplet PCR, we achieved highly sensitive quantification of rare genetic mutations in liquid biopsy samples.	10	29	TECHNIQUE	digital droplet PCR
Utilizing RNA-seq, we quantified the differential gene expression profiles of treated versus untreated cells, providing insights into the molecular mechanisms of drug response.	10	17	TECHNIQUE	RNA-seq
Utilizing whole-exome sequencing, we pinpointed mutations in the coding regions that are responsible for monogenic disorders, aiding in the diagnosis and treatment.	10	32	TECHNIQUE	whole-exome sequencing
We demonstrated that INTERSTELLAR successfully extracted information from a range of short- and long-read sequencing reads and translated those of single-cell (sc)RNA-seq, scATAC-seq, and spatial transcriptomics to be analyzed by different software tools that have been developed for conceptually the same types of experiments	172	182	TECHNIQUE	scATAC-seq
We demonstrated that INTERSTELLAR successfully extracted information from a range of short- and long-read sequencing reads and translated those of single-cell (sc)RNA-seq, scATAC-seq, and spatial transcriptomics to be analyzed by different software tools that have been developed for conceptually the same types of experiments	196	211	TECHNIQUE	transcriptomics
We employed polymerase chain reaction (PCR) to amplify specific DNA fragments, facilitating the detection of pathogen presence in clinical samples.	12	37	TECHNIQUE	polymerase chain reaction
We further conducted RNA sequencing analysis to clarify the potential underlying mechanism of the anti-depressive effect of 1-MT in HFD-induced depressive mice	21	44	TECHNIQUE	RNA sequencing analysis
We performed integrative genomic analysis combining whole-genome sequencing and transcriptomics to uncover regulatory mechanisms in disease.	13	41	TECHNIQUE	integrative genomic analysis
We used single-cell ATAC-seq to profile chromatin accessibility in individual cells, shedding light on gene regulatory mechanisms.	8	28	TECHNIQUE	single-cell ATAC-seq
We utilized bioinformatics tools to analyze the high-throughput sequencing data, providing insights into the genetic architecture of the population.	12	32	TECHNIQUE	bioinformatics tools
With the availability of whole-genome single-nucleotide polymorphism (SNP) maps, it will soon be possible to create an SNP profile for patients who experience adverse events (AEs) or who respond clinically to the medicine (efficacy).	25	37	TECHNIQUE	whole-genome
Recent advances in next-generation sequencing (NGS) have resulted in the identification of tens of thousands of rare pharmacogenetic variations with unknown functional effects.	47	50	TECHNIQUE	NGS
Recent advances in next-generation sequencing (NGS) have resulted in the identification of tens of thousands of rare pharmacogenetic variations with unknown functional effects.	19	45	TECHNIQUE	next-generation sequencing
Genome sequencing is enabling precision medicinetailoring treatment to the unique constellation of variants in an individuals genome.	0	17	TECHNIQUE	Genome sequencing
St Catherine Specialty Hospital in Zagreb/Zabok, Croatia has implemented a personalized patient approach using the RightMed Comprehensive PGx panel of 25 pharmacogenes plus Facor V Leiden, Factor II and MTHFR genes, which is interpreted by a special counseling team to offer the best quality of care.	139	148	TECHNIQUE	PGx panel
This work advances the use of nanopore sequencing in clinical PGx settings.	30	49	TECHNIQUE	nanopore sequencing
SULT1A1 mRNA and protein levels were quantified using microarray data and Western blot analysis, respectively	74	86	TECHNIQUE	Western blot
Differing from the widely used PCR, the SmartAmp reaction is an isothermal DNA amplification, where the initial step of copying a target sequence from the template DNA is critically important	40	57	TECHNIQUE	SmartAmp reaction
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	89	100	TECHNIQUE	Taqman qPCR
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	105	133	TECHNIQUE	Second-Generation Sequencing
